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Tuberculosis (TB) caused by the bacterium, Mycobacterium tuberculosis (M.tb) has resulted 
in an unprecedented number of deaths over centuries.  L,D-transpeptidase enzymes are known 
to play a crucial role in the biosynthesis of the cell wall, which confers resistance to most 
antibiotics.  These enzymes catalyze the 3→3 peptidoglycan cross-links of the M.tb cell wall.  
Specific β-lactam antibiotics (carbapenems) have been reported to inhibit cell wall 
polymerization of M.tb and they inactivate L,D-transpeptidases through acylation.  L,D-
transpeptidase 5 (LdtMt5) is a unique paralog and a vital protein in maintaining integrity of the 
cell wall specifically in peptidoglycan metabolism therefore making it an important protein 
target.  Carbapenems inhibit LdtMt2, but do not show reasonable inhibitory activities against 
LdtMt5.  We therefore sought to perform virtual screening in order to acquire potential inhibitors 
against LdtMt5 and to investigate the affinity and to calculate the binding free energies between 
LdtMt5 and potential inhibitors.  Furthermore, we sought to investigate the nature of the 
transition state involved in the catalytic reaction mechanism; to determine the activation free 
energies of the mechanism using ONIOM through the thermodynamics and energetics of the 
reaction path and lastly to express, purify and perform inhibition studies on LdtMt5.   
A total of 12766 compounds were computationally screened from the ZINC database to 
identify potential leads against LdtMt5.  Docking was performed using two different software 
programs.  Molecular dynamics (MD) simulations were subsequently performed on 
compounds obtained through virtual screening.  Density functional theory (DFT) calculations 
were then carried out to understand the catalytic mechanism of LdtMt5 with respect to β-lactam 
derivatives using a hybrid ONIOM quantum mechanics/molecular mechanics (QM/MM) 
method.  LdtMt5 complexes with six selected β-lactam compounds were evaluated.  Finally, a 
lyophilised pET28a-LdtMt5 was used to transform E. coli strain BL21 (DE3) and SDS-PAGE 
was used to verify the purity, molecular weight and protein profile determination.  Finally, an 
in vitro binding thermodynamics analysis using isothermal titration calorimetry (ITC) was later 
on performed on a single compound (the strongest binder) from the final set, in a bid to further 
validate the calculated binding energy values.   
A number of compounds from four different antimicrobial classes (n = 98) were obtained from 
the virtual screening and those with docking scores ranging from -7.2 to -9.9 kcal mol-1 were 
considered for MD analysis (n = 37).  A final set of 10 compounds which exhibited the greatest 
affinity, from four antibiotic classes was selected and Molecular Mechanics/Generalized Born 
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Surface Area (MM-GBSA) binding free energies (ΔGbind) from the set were characterised.  The 
calculated binding free energies ranged from -30.68 to -48.52 kcal mol-1.  The β-lactam class 
of compounds demonstrated the highest ΔGbind and also the gretaest number of potential 
inhibitors.  The DFT activation energies (∆G#) obtained for the acylation of LdtMt5 by the six 
selected β-lactams were calculated as 13.67, 20.90, 22.88, 24.29, 27.86 and 28.26 kcal mol-1.  
The ∆G# results from the 6-membered ring transition state (TS) revealed that all selected six β-
lactams were thermodynamically more favourable than previously calculated activation energy 
values for imipenem and meropenem complexed with LdtMt5.  The results are also comparable 
to those observed for LdtMt2, however for compound 1 the values are considerably lower than 
those obtained for meropenem and imipenem in complex with LdtMt2, thus suggesting in theory 
that compound 1 is a more potent inhibitor of LdtMt5.  We also report the successful expression 
and and purification of LdtMt5, however the molecule selected for the in vitro inhibition study 
gave a poor result.  On further review, we concluded that the main cause of this outcome was 
due to the relatively low insolubility of the compound.   
The outcome of this study provides insight into the design of potential novel leads for LdtMt5.  
Our screening obtained ten novel compounds from four different antimicrobial classes.  We 
suggest that further in vitro binding thermodynamics analysis of the novel compounds from 
the four classes, including the carbapenems be performed to evaluate inhibition of these 
compounds on LdtMt5.  If the experimental observations suggest binding affinity to the protein, 
catalytic mechanistic studies can be undertaken.  These results will also be used to verify or 
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1.1 Global Tuberculosis burden 
Tuberculosis (TB) on the global scale of infectious diseases has the highest mortality rate to 
date, resulting in 1.8 million deaths per year1.  With such human carnage, tuberculosis was 
declared a global emergency in 19933.  The current global incidence of the disease as of year 
2016 stands at 10.4 million4.  This was facilitated by multi-drug resistant (MDR) and 
extensively drug resistant (XDR) Mycobacterium tuberculosis (M.tb) strains, which render the 
available antibacterial drug regimens compromised5-7.  Drug-resistant TB is responsible for a 
yearly mortality of 250 000 and multi drug-resistant TB patients require a complicated 
multidrug treatment.  Only 52 % of MDR-TB patients are successfully treated globally and 
only a finite number of second-line medicines are available.  It is also estimated that in 50 % 
of MDR TB patients worldwide, there is second-line drug resistance and the treatment of XDR 
TB is successful in only one third of the patients1, 8.  This resistance does not only encumber 
the capacity to treat bacterial infections but has extensive socio-economic implications.  Such 
a situation creates an urgent need to develop antimicrobial drugs suitable to counteract the ever-
evolving bacterium M.tb8. 
Tuberculosis and HIV-1 epidemics are closely related in South Africa9, 10.  It has been identified 
that almost all patients with XDR tuberculosis are HIV-positive9, 11.  This deadly synergy brings 
about a fatal outcome, with high mortality rates in co-infected patients9.  It was also revealed 
through phylogenetic analysis that in spite of stringent treatment adherence, there was a 
stepwise evolution of drug resistance, thus suggesting that the existing TB drug regimens are 
inadequate to curb the spread of drug-resistant TB within this HIV co-infected population12.  
Data from several studies strongly suggests the need to strengthen the existing interventions in 
order to prevent the spread of this likely incurable disease and public health scourge9, 11-14.  To 
improve the probability of finding new effective drugs against MDR and XDR TB, whole cell 
and targeted drug design approaches were therefore suggested by Kana et al.15, as a multi-
disciplinary approach is bound to yield better results.  The whole cell approach provides novel 
and chemically validated targets, useful for target-based optimization of compounds.  The 
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targeted drug design approach can be utilised to improve the efficiency of the drug discovery 
process for TB, by reducing attrition in processes of hit isolation and optimization15. 
L,D-transpeptidases (LDTs) are essential for peptidoglycan biosynthesis in M.tb and targeting 
them is likely to be effective in controlling the bacterium.  Recent findings revealed that 
carbapenems fail to inactivate LdtMt5
16, a unique protein responsible for maintaining the 
integrity of the cell wall therefore making it an important M.tb target17.  Despite several 
theoretical studies on LdtMt2
18-23, and a few experimental studies on LdtMt5
16, 17, to the best of 
our knowledge there has been no computational study on the structure and function of LdtMt5 
as well as identifying potential inhibitors effective against LdtMt5.  A need to perform virtual 
screening of various inhibitors against LdtMt5 therefore exists.  Furthermore, this study will 
seek to investigate the interactions and binding free energy between LdtMt5 and potential 
inhibitors using molecular dynamics (MD) simulations, to evaluate the mechanistic reaction 
between β-lactams and LdtMt5 and the in vitro validation of the screened inhibitors. 
1.1.1 Infection life cycle of Mycobacterium tuberculosis 
Tuberculosis can be transmitted from an infected person as a colloid through coughing24.  An 
initial infection triggers the production of chemokines and cytokines which direct the migration 
of phagocytes to the infected areas such as lungs25, 26.  This movement works to the advantage 
of the mycobacterium in that it resides in these phagocytic cells and it has developed several 
mechanisms to exploit the expansive cellular niche24.  The host’s professional phagocytic cells 
include dendritic cells, macrophages, monocytes and neutrophils26.  The M.tb survival 
mechanisms include resistance to reactive oxygen intermediates (ROIs), such as hydrogen 
peroxide27 and hydroxyl radicals28; nitric oxide and reactive nitrogen radicals (RNI) tolerance29, 
30; inhibition of phagosome maturation31; translocation of the mycobacterium to the cytosol to 
avoid phagolysosomal degradation32; apoptosis inhibition33 and mycobacterium-induced 
macrophage necrosis34.  A critical balance or equilibrium is subsequently reached between the 
host’s immune system and mycobacterium adaptation resulting in a process called latency.  
Latent TB can develop into active TB which is characterized by coughing and increased 
production of sputum.  The activation of TB is mainly attributed to a compromised or defective 
immune system.  Two mechanisms of reactivation have been established in the human host: 




1.1.2 Mycobacteria cell wall 
The mycobacterial cell wall (envelope) is a complex structural feature, distinct from other 
prokaryotes37.  It is essential for the well-being of the organism and it serves in the control of 
the movement of substances in and out of the cell.  In principle it consists of three main 
components i.e. capsule, cell wall and membrane38. 
1.1.2.1 The structural cell wall of Mycobacterium tuberculosis 
The cell envelope possesses structures which are not found in animal cells, but unique to 
mycobacteria thereby making it a lucrative target for selective inhibition38.  Antibiotic and 
chemotherapeutic agent resistance of M.tb has been attributed to the relatively unyielding 
bacterial and cellular impermeability of the cell wall.  The primary structure of the cell wall is 
commonly referred to as the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex37 or the 
‘core’  can be described as a dynamic and asymmetric lipid bilayer39.  It has soluble and 
insoluble fractions.  The soluble lipid upper layer above the mycolic acids is made up of free 
lipids which comprise of cord factor, sulpholipids and phthioceroldimycocerates (PDIM)40.  It 
is composed of an assortment free long chain and short α-chain lipids40.  There are 70-90 
carbon-containing lipids known as mycolic acids within that region41, 42.  These lipids are 
occasionally interrupted by proteins known as phosphatidylinositol mannosides (PIMs) and 
two types of lipids, lipoarabinomannan (LAM) and lipomannan (LM)40.  The lower section is 
composed of peptidoglycan (PG), covalently attached to arabinogalactan (AG) which is 
connected to the mycolic acids40, 42 (Figure 1).  This is the highly insoluble and impermeable 




Figure 1. The cell wall of Mycobacterium tuberculosis exhibiting its various structural components 
(Image use permission granted by © SAGE Publications Copyright © 201343) 
 
The peptidoglycan or murein layer is a mesh-like rigid structure which offers a structural 
scaffold to the cell to withstanding osmotic pressure and maintaining cellular integrity37.  It is 
composed of repeating N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) 
residues linked by β (1→4) glycosidic bonds.  N-acetylmuramic acid residues are a 
combination of N-acetyl and N-glycolyl groups, in which N-acetyl would be oxidised to 
MurNGly, which is an N-gylcolyl function44.  The reason for the structural modification and 
oxidation is not clear, however, it is speculated that they provide the additional strength to the 
mesh through hydrogen bonds45, 46.  The side chains (four or five amino acid peptides long) 
made up of L-alaninyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine are crosslinked with 
peptides of adjacent glycan linkages.   
1.1.2.2 Peptidoglycan layer of Mycobacterium tuberculosis  
Peptidoglycan biosynthesis starts in the cytoplasm since soluble amino acids and nucleotide 
activated sugars are required to initiate the process37.  UDP-GlcNAc is the starter molecule 
which is synthesized in a four-stage process involving three enzymes.  D-fructose-6-phosphate 
is first converted to D-glucosamine-1-phosphate which is converted to D-glucosamine-6-
phosphate, then catalysed to form UDP-GlcNAc.  The enzymes involved are GlmS an 
aminotransferase, GlmM a mutase and GlmU respectively47.  GlmU performs both acetylation 
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and uridylation48.  The carboxy-terminal domain of GluU catalyses the acylation of D-
glucosamine-6-phosphate and uridylation of N-acetylglucosamine-1-phosphate is carried out 
on the amino-terminal domain49.  The UDP-GlcNAc is further converted to UDP-MurNAc in 
two stages catalysed by the enzymes MurA, an enolpyruvyl transferase and MurB, a reductase.  
The process in which MurA catalyses the movement of enolpyruvate from 
phosphoenoylpyruvate to position-3 of N-acetylglucosamine portion of UDP-GlcNAc thereby 
releasing inorganic phosphate50.  MurB catalyses the production of UDP-MurNAc utilising 
NADPH thus transforming the enolpyruvate into D-lactoyl37.  Muramic acid ligase enzymes 
MurC, MurD, MurE and MurF sequentially catalyse the synthesis of either UDP-N-
acetylmuramyl pentapeptide from UDP-MurNAc or UDP-N-glycolylmuramylpentapeptide 
from UDPMurNGlyc37.  These enzymes are functionally intracellular ATP-dependent.  Within 
the peptidoglycan pathway, amino acid residues are added by the ligase enzymes to form UDP-
MurNAc and UDP-MurNGlyc intermediates.  L-alanine and D-glutamate are added by MurC 
and MurD respectively, while  meso-DAP, and D-alanyl-D-alanine, are added by MurE and 
MurF51.  Common within the Mur ligases is the addition of a carboxyl group to the uridine 
diphosphate substrate via phosphorylation by adenosine triphosphate, to produce adenosine 
diphosphate.  An amino acid or dipeptide attack on the UDP-substrate phospho-intermediate 
ensues, resulting in adjunction via amino-acylation of the uridine diphosphate precursor 
thereby expelling inorganic phosphate52, 53.  M. tuberculosis MurC ligates both L-alanine and 





Alr and Ddl are other enzymes crucial in the cytoplasmic assembly of PG by providing 
racemase and ligase activity, respectively55.  Polyprenyl phosphates are critical in the 
biosynthesis of the cell envelop, by making a lipid anchor which permits the synthesis of the 
Figure 2. Biosynthesis of mycolic acid-arabinogalactan-peptidoglycan complex (MAPc) belonging to 
M.tb, according to contemporary knowledge of MAPc structure and the activities of known proteins 
(italicised) expressed by M.tb. There are many enzymes associated with the mycolic acids synthesis, 
however some are not listed (Image adopted and redrawn from Crick et al.2) 
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cell wall to happen whilst firmly attached onto a cytoplasmic membrane34.  MurX is an enzyme 
which relays phospho-MurNAc-pentapeptide to decaprenol phosphate lipid which is a long 
carbon chain unique to mycobacteria, to form lipid I from Park’s nucleotide.  MurG, a 
glycosyltransferase uses UDP-GlcNAc making a β (1→4) glycosidic bond on GlcNAc and 
MurNAc or MurNGlyc sugar belonging to lipid I to form lipid II thus concluding the 
cytoplasmic pathway of PG biosynthesis34.  The plasma membrane and the periplasmic space 
are the sites where the other reaction involved in PG biosynthesis take place.  In mycobacterial 
cells, lipid II makes a demarcation between the cytoplasm and periplasmic space37.  
Translocation of lipid II across the plasma membrane is carried out by two proteins namely 
MurJ and FtsW.  Lipid II is a substrate for two penicillin-binding proteins, PonA1 and PonA2 
which perform transglycolase and transpeptidase reactions56, 57.  Both proteins are crucial in 
the maintenance of cell integrity and viability in mycobacteria.  Studies have shown that PonA1 
is important in the modulation of peptidoglycan hydrolysis through its interaction with the 
RipA-RpfB complex, while PonA2 being a vital protein for dormancy in M.tb58. 
1.1.2.3 Transpeptidases and mycobacterial cell wall biosynthesis 
In many bacterial species peptidoglycan cross-linking is mainly carried out by D,D-
transpeptidases which are also known as classical penicillin binding proteins (PDBs).  However 
the activity of these enzymes can be bypassed by another family of transpeptidase enzymes 
called L,D-transpeptidases59, 60.  Contrary to other bacteria, M.tb peptidoglycan cross-linking 
is predominantly performed by the L,D-transpeptidases.  The D,D and L,D-transpeptidases are 
peptidoglycan polymerases which are structurally different, whereby they contain different 
active-site nucleophiles, the former having serine and the latter, cysteine59, 61.  D,D-
transpeptidases  catalyse the formation of 4→3 peptidoglycan cross-links while L,D-
transpeptidases form 3→3 crosslinks.  In bacterial peptidoglycan crosslinking, a pair of stem 
peptides from adjoining glycan chains function as acyl donor and acceptor60.  D,D-
transpeptidases have a pentapeptide donor stem on which they split a  D-Ala4–D-Ala5 (D,D) 
bond and a carbonyl of D-Ala4 is connected to an amine on the third residue of the acceptor 
thereby form 4→3 cross-links60, 61.  The L,D-transpeptidases possess a tetrapeptide donor stem 
and they cleave the L-Lys3–D-Ala4 (L,D) peptide bond from the acyl donor linking it to same 
acceptor (the carbonyl of D-Ala4) to generate the 3→3 cross-links60, 61.  Among all known 
bacteria M.tb is the only one expressing a high (80 %) percentage of 3→3 cross-links62.  There 
is a difference in the peptidoglycan of actively replicating and dormant M.tb.  The 4→3 trans-
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peptide bonds mainly occur in the active M.tb while the non-replicating M.tb contains 
significantly more 3→3 linkages37. 
1.1.2.4 Inhibition of L,D Transpeptidase enzymes 
L,D-transpeptidase enzymes are non-classical transpeptidases which are inhibited by a class of 
β-lactams, known as carbapenems, especially meropenem.  The cysteine active residues of LDTs 
react forming thioester bonds with the β-lactam ring.  Carbapenems in collaboration with 
clavulanic acid were shown to be effective against XDR strains of M.tb63.  Clavulanate is a 
chemical compound which inhibits broad-spectrum BlaC β-lactamase irreversibly64.  L,D-
transpeptidases are essential proteins for peptidoglycan biosynthesis in M.tb and targeting them 
is likely to effectively control M.tb.  Mycobacterium tuberculosis produces five paralogs of the 
enzyme (LdtMt1 to LdtMt5)
21 and the cause of such a redundancy is not yet understood.  The 
most dominant and widely studied L,D-transpeptidase enzyme is LdtMt2.  Recent findings, 
however revealed that carbapenems fail to inactivate the paralog LdtMt5.  Cordillot et al. 
investigated peptidoglycan inhibition by β-lactams, and all five M.tb LDT paralogs were 
characterized according to acylation and peptidoglycan dimer formation by carbapenems16.  It 
was discovered that the carbapenems failed to inactivate LdtMt5 and the enzyme remained active 
in the peptidoglycan cross-linking assay.  The study concluded that the antibacterial activity of 
carbapenems infer that LdtMt5 is unique and it is not capable to compensate for the activity of 
other LDTs16.  An experimental study conducted by Basta et al. determined the first crystal 
structures of the apo-form and Meropenem-bound LdtMt5 and it was shown that the active site 
of LdtMt5 possessed a structurally unique catalytic site which had a proline-rich C-terminal 
subdomain.  Furthermore, it was discovered that M.tb lacking a functional copy of LdtMt5 was 
vulnerable to denaturation by certain carbapenems, osmotic shock and crystal violet17.  This 
strongly suggests that LdtMt5 is not a mere functionally redundant paralog, but it is a unique 
and vital protein in maintaining integrity of the cell wall specifically in peptidoglycan 
metabolism therefore making it an important protein target17. 
1.1.2.5 Computational studies on L,D Transpeptidase enzymes 
A number of computational studies have previously been performed on L,D-transpeptidases18-
23, 65, 66.  The reaction mechanism of (LdtMt2) from M.tb with its natural substrate was evaluated 
through hybrid quantum mechanics/molecular mechanic (QM/MM) simulations and umbrella 
sampling20.  The binding energies from the QM/MM MD simulations and the free energy 
profile associated with the catalytic mechanism of LdtMt2
20 were in line with the isothermal 
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titration calorimetry (ITC) experimental binding energy trend and they revealed that acylation 
was the rate-limiting step21.  Based on experimental findings, the reaction of joining of m-
A2pm3 residue to m-A2pm3, involves acylation and deacylation21.  The acylation stage is 
characterised by the formation of a thiolate/imidazole ion-pair (a zwitterion) and a nucleophilic 
attack on the carboxyl carbon of the substrate subsequently resulting in the peptide bond 
breaking.  Silva et al. also conducted a study on the inactivation of LdtMt2 by the carbapenems, 
imipenem and meropenem using QM/MM simulations and an umbrella sampling19.  Using 
density functional tight binding/molecular mechanics (DFTB/MM), a four-membered ring 
transition state was obtained and the theoretical energetics confirmed the previously reported 
experimental results67.  Another theoretical study aimed at determining the mode of interactions 
of different carbapenems within the active site of  LdtMt2 was performed using the MM-GBSA 
and SIE binding free energy approach18.  Results from the study revealed a direct correlation 
between the energy of the inhibitor-LdtMt2 pre-complexes and the free energies of the 
covalently bound inhibitor-LdtMt2 complexes.  This was however contrary to what was 
demonstrated by experimental data21. 
Using the DFT approach, Fakhar et al. conducted a mechanistic study of the carbapenems with 
LdtMt2 and came up with an acylation step model of the β-lactam ring.  The study propounded 
three reaction pathways involving four-membered rings (TS-4, TS-4-His and TS-4-water) and 
one pathway involving a six-membered ring (TS-6-water).  All the four suggested pathways 
revealed different transition states.  It was concluded that the TS-6-water model best described 
the reaction mechanics.  A study on the flap dynamics of LdtMt2 was also performed through 
MD simulations to evaluate the impact of induced conformational changes of  the flap region 
during the binding process22.  The MM-GBSA method had revealed greater binding energy for 
values imipenem complex with LdtMt2 as compared to the complexes with ertapenem and 
meropenem23.  However, according to the dynamic cross-correlation matrix (DCCM) analysis 
there were strong anti-correlated motions in the imipenem-LdtMt2 flap whereas binding to 
ertapenem and meropenem induced a shift to correlation motion within flap units22.  Various 
other experimental16, 21, 68-73 and theoretical studies6, 19, 20, 22, 23, 74, 75 have been performed on 
LdtMt2.  Our group has recently proposed a plausible mechanism for the interaction between 
the LdtMt2 enzyme and carbapenems.  A theoretical investigation of the same computational 




1.2 Computational methods 
Computer-aided drug design (CADD) techniques have been crucial in the discovery and 
development of small molecules with therapeutic importance.  There are basically two 
categories i.e. ligand-based and structure-based methods76, 77.  Ligand-based methods make use 
of ligand information only, to predict activity based on similarity to known active ligands and 
tools such as homology modelling are utilised.  Structure-based use both target and ligand 
structure information and utilities such as molecular docking are commonly employed76, 77.  
Ultimately compound databases are virtually screened to obtain ligands with potent therapeutic 
properties. 
1.2.1 Virtual Screening 
Virtual screening (VS) is a crucial computational technique in contemporary drug design and 
discovery to explore compound libraries, aimed at identifying putative binders for a specific 
drug target.  It is effective in reducing the immense chemical space of huge databases to a 
smaller size that can be evaluated experimentally78.  Structure-based virtual screening (SBVS) 
also known as neighbourhood behaviour search is the computational screening of small 
molecules for potential candidate ligands through docking into the binding structure of a 
protein receptor79.  The technique offers greater possibility to discover novel ligands, however 
its success heavily relies on the quality of the receptor structure and the accuracy of the scoring 
function used to measure the binding affinity between a ligand and a receptor80.  Modern 
technological advances in computational and bioinformatics have allowed for rapid chemical 
and biological data mining in search of novel compounds in a short space of time and limited 
computational expense.  Structure-based virtual screening normally uses docking techniques 
and both free and commercially available docking software can be used to perform the ligand 
docking81. 
Docking principally involves the prediction of ligand orientation within a receptor binding 
site82.  Fundamentally, all docking programs have conformational search algorithm which 
scouts for the best fit of inhibitors in the active site of the enzyme and a scoring function which 
ranks the various conformations as intermolecular binding energy60.  The docking process is 
essential for the 3-dimensional (3D) structure modelling of the receptor-ligand complex and it 
is useful for analysing the strength of the interactions which determine molecular recognition.  
It is used for exploring conformations of a ligand within the binding pocket and estimation of 
their binding affinities82.  This process is referred to as virtual screening when it is automated 
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for a large data set of ligands.  Rigid docking and flexible docking are the two main forms of 
the docking technique.  Rigid docking is a procedure that performs rigid body search and it is 
reliable only if the ligand molecule has a few rotatable bonds and does not assume multiple 
conformations within the active site.  Flexible docking allows for ligand flexibility of both the 
ligand and the enzyme.  The multiple rotatable bonds of the ligand and also of the amino acid 
residues are allowed to freely orient themselves to attain the best conformation possible82, 83. 
A review by Honarparvar et al. comprehensively discusses the molecular docking process60.  It 
emphases the importance of confirming the flexibility of both the ligand molecule and the 
enzyme target when docking.  It was revealed that flexible targets could undergo 
conformational changes upon binding a ligand, thus potentially affect the docking accuracy.  
The number of active sites on an enzyme is also of paramount importance since it is bound to 
affect the binding of ligand molecules.  It was further highlighted in the review that the binding 
affinities of ligand molecules to the enzyme obtained from docking provide a general insight 
on the correlation on the activity of an inhibitor on an enzyme, but this approach has not always 
been reliable, since these are estimations60.  Docking algorithms of SBVS are generally 
classified into three categories based on the search method i.e. algorithms that search the 
conformational space during docking (Monte Carlo algorithm and Genetic algorithm); 
algorithms searching the space before docking and algorithms performing incremental 
docking84.  There are two types of failures protein-ligand docking predictions namely, soft and 
hard failures.  A soft failure is a result of limitations in the search algorithm whereby the 
algorithm fails to locate the global energy minimum which corresponds to the crystal structure.  
A hard failure arises when the global energy minimum is corresponding to a mis-docked 
structure and the energy being lower than that of the minimized crystal structure.  Such a failure 
emanates from inaccuracies in reproducing variability in the energies of other binding modes85. 
Scoring functions serve to distinguish the different poses (conformations) assumed by a ligand 
within the binding pocket of a receptor and following a docking procedure, the functions 
predict the binding affinities of various receptor-ligand complexes through ranking83.  The 
scoring functions utilised in docking software applications apply certain assumptions in the 
evaluation of modelled complexes, therefore they are not able to account for the physical 
interactions that facilitate ligand binding such as hydrogen bonding, hydrophobic and solvation 
effects, Van der Waal’s, steric and electrostatic interactions which are governed by kinetic and 
thermodynamic principles86.  Scoring functions improve the effectiveness of docking 
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algorithms, however the binding affinities are estimated.  There are four types of scoring 
functions available: consensus scoring, empirical-based, force-field based and knowledge-
based scoring84.  The review by Reddy et al. performed an appraisal on the available virtual 
screening methods and recent developments of the docking and similarity based methods84.  
Another review evaluated the various available docking software programs87. 
It is however important to realise that virtual screening has its draw backs.  A review by Scior 
et al. critically evaluated the virtual screening technique and four major categories of classical 
limitations were highlighted and further discussed in detail.  These limitations regard inaccurate 
assumptions and expectations; data design and content; some relate to the software choice and 
others are due to conformational sampling as well as protein and ligand flexibility88.  In spite 
of the limitations highlighted, virtual screening plays an important role in drug discovery and 
development. 
1.2.2 Molecular Dynamics (MD) Simulation 
Molecular dynamics simulations are calculations which seek to describe the complex 
interactions (fluctuations and conformational changes of molecules) in biomolecular systems 
through computational models. A number of review articles89-103 and textbooks104-107 describe 
in detail the theory behind MD free energy calculations and its application to biomolecular 
systems.  Different computational software such as  Amber108, ICM109, and NAMD110 can be 
used to perform MD simulations.  Generally, a molecular system is initially modelled from 
either experimental structures or comparative modelling data111.  All the forces exerted on the 
atoms in the system are then estimated from molecular mechanics principles.  Simulations are 
typically performed on clusters or supercomputers because of the enormous amount of 
calculations required.  The model which best reproduces the actual molecular interactions is 
the atomistic representation, which includes aspects such as bond angles, bond length and bond 
rotations112.  Bonded and non-bonded atomic interactions, which produce Van der Waals and 
electrostatic forces, need to be taken into consideration and these are governed by quantum-
mechanical laws such as Coulomb’s law, Lennard-Jones potentials and Newtonian laws113, 114.  
Solvent representation is of paramount importance in system definition.  In order to 
characterise the solvation effects of a real solvent such as hydrophobic effects, explicit 
solvation needs to be considered112.  Force-fields are complicated equations which are aimed 
at deducing potential energy from the molecular structure.  They are computational parameters 
summing up the various atomic forces that govern molecular dynamics of a particular system.  
30 
 
Different force fields are employed in MD simulations and they are fine-tuned with different 
parameters but generally giving similar results115.  Common examples include AMBER108, 
CHARMM116 and GROMOS117.  
In the present study the AMBER MD software package will be utilised for various simulations. 
The AMBER force fields are described as follows113: 
EAMBER = Eangle + Ebond + Edihedral + Enon-bonded   (1) 
Eangle are bond angle approximations whereas and Ebond are strain energies.  The Edihedral is the 
energy interaction involving the dihedral angles of four atoms linearly-bonded.  Enon-bonded 
denotes the systems’ non-bonded interactions composed of an electrostatic potential; Lennard-
Jones potential for the van der Waals forces and the Pauli repulsion potential114.  The AMBER 
force field (GAFF) has parameters fine-tuned for simulations involving proteins, nucleic acids 
and small organic compounds such as enzyme inhibitors118.  Molecular dynamics simulations 
are important in describing molecular interactions, however their utility should not be 
overemphasised.  There is need to perform studies comparing the simulations with 
experimental data in order to validate the computational model111. 
1.2.3 Molecular Mechanics (MM)  
Molecular mechanics utilise the established traditional approach to estimate the total energy of 
a molecule with relation to its conformation119.  It is very useful in deducing the potential 
energy for molecular dynamics simulations on complex molecules.  Aspects such as transition 
states and geometries can be predicted and the relative energies between molecules can also be 
deduced120, 121.  The greatest advantage of this method is that the computational cost of 
molecular mechanics is minimum.  However, force field methods disregard the influence of 
electrons, electronic rearrangements (charge transfer, and/or electronic excitation) and bond 
breaking/formation, as a result this makes them inadequate to describe complex systems120-122.  
Considering the limitations of both approaches (QM and MM), hybrid methods have become 
popular and effective solutions for dealing with complex systems. 
1.2.4 Quantum Mechanics (QM) 
Quantum mechanics play a crucial role in investigating the mechanisms, which are involved in 
biochemical systems121.  Owing to the rapid advancement in the development of super 
computers, QM can be harnessed to accurately predict the physical properties of reactions and 
provide reliable information on electronic properties, energies, geometries and reactivities of 
molecules121, 122.  However, to accurately model complex systems such as protein structures, 
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the quantum mechanics method is limited in terms of high computational cost.  In a bid to avert 
this challenge, a small but most significant portion of the system such as the active site only, is 
often considered at the QM level for the modelling120.  The major setback of this approach is 
that it often leads to insufficient description of the system as a whole, which may result in 
misleading conclusions.  Several textbooks discuss the principles and applications of quantum 
mechanics123-126. 
1.2.5 Hybrid quantum mechanics/molecular mechanics (QM/MM)  
Quantum mechanics/molecular mechanics simulations are hybrid molecular simulation 
methods which incorporate the precision of quantum mechanics and the speed of molecular 
mechanics to evaluate chemical reactions in condensed phases127, 128.  This allows the study of 
complex  biochemical systems i.e. enzymes.  In principle the system separates into 
compartments in which the reaction centre is subjected to the more precise and costly QM 
approach and the ‘spectator’ system is evaluated using the less accurate but efficient MM 
classical approach119, 122.  Electrostatic interactions between the QM and MM region are 
categorised as either mechanical embedding or electrostatic embedding.  Mechanical (classical) 
embedding is simple, and it deals with electrostatic interactions using low level theory at the 
MM level120, 122.  The disadvantage of this method is that it is difficult to assign appropriate 
MM properties (e.g. atom centred point charges) to the QM region and its inability to consider 
the effects of electrostatic interactions on the electronic structure of the QM system119.  
Electrostatic embedding is an alternative method in which there is direct coupling of the QM 
wave function and the MM region129.  Electronic interactions of the QM and MM region are 
integrated over the QM charge density119, 120.  Based on the partitioning strategy, there exists 
two different forms of QM/MM of Hamiltonian known as subtractive and additive forms130. 
For the subtractive approach, the total energy EQM/MM is derived in a three-phase process.  
Firstly, at the MM level, the energy EMM (QM+MM) of the whole system (comprising both 
QM and MM sections) is estimated.  This is then followed by the addition of the QM energy 
of the separated QM sub-region which is denoted EQM(QM)
120.  Thirdly, the MM energy of the 
QM sub-region EMM(QM) is then calculated and deducted.  The equation below sums up the 
subtractive QM/MM method as follows: 
EQM/MM = EMM (QM+MM) + EQM(QM) – EMM(QM)  (2) 
The advantages of this method are that it is very efficient and simple to implement since there 
no contact is necessary within the QM and MM aspects of the system120, 121.  However, the 
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main setback of the approach is the limited availability of the force field to the QM portion and 
its lack of insufficient flexibility to describe certain changes occurring in chemical reactions122.  
The most popular subtractive QM/MM method is ONIOM (our Own N-layer Integrated 
molecular Orbital molecular Mechanics)121, 131.  A review on the principles and applications of 
these methods appeared in 2012130. 
1.2.5.1 ONIOM 
ONIOM is a reliable hybrid subtractive QM/MM method capable of performing a high-level 
QM calculation on a small selected region of the system while incorporating the environmental 
(lower-level) effects thus producing a consistent energy expression121, 131.  This means that 
large and complex molecular systems can be calculated to produce energy and geometry with 
accuracy highly comparable to smaller systems,  using limited computational resources through 
simple linear extrapolation121.  The ONIOM method is flexible and versatile since 
approximations can be easily defined and performed as two-layer ONIOM (QM1:QM2), three-
layer ONIOM (QM1:QM2:MM), or multi-layer model128, 131, 132.  This hierarchical application 
of method makes it a unique hybrid QM/MM method128, 132.  A recent review on the ONIOM 
method discussed the parameterization procedures and applications to varying classes of 
molecules and systems121. 
1.3 Experimental Methods 
The main goal of pharmaceutical research is to discover and develop novel compounds capable 
of the influencing structure and regulating the function of disease-associated proteins133.  
Accurate knowledge of the structure and function of such proteins is of paramount importance 
in drug development.  The initial step in contemporary drug discovery is the identification of 
biomolecules such as essential proteins which are directly involved in disease initiation and 
progression.  This is then followed by the discovery of novel pharmaceutical compounds 
through searching for small drug-like molecules, (with small molecular weight) with 
‘promising’ therapeutic effects133.  These drug compounds can exhibit their therapeutic 
potential by inhibiting specific proteins or activating biomolecular signals via protein-protein 
and/or protein-DNA interactions.  In vitro and in vivo tests are then carried out to evaluate the 
inhibitory effects of the identified compounds.  The most common targets of drugs are enzymes 
since they take part in important biochemical events.   
Advances in bioinformatics, genomics and proteomics have facilitated the application of 
various recombinant DNA techniques to evaluate the protein of interest134.  Protein expression 
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together with protein purification are important tools extensively used in biopharmaceutical 
research for the preparation of pure proteins for various purposes such as antibody production, 
crystallization and kinetic studies.  The success of any drug discovery study relies on the 
appropriate selection of an expression system as well as the optimization of experimental 
conditions135.  In the current study, the aforementioned techniques will be used to prepare the 
enzyme, LdtMt5 of M.tb to evaluate the binding of the computationally screened compounds. 
1.3.1 Protein expression 
Protein expression involves transcription and translation that is the creation of a copy of genetic 
information in the nucleus and copying of information to synthesize protein respectively136.  It 
is one of the most important processes in biological systems.  Important in heterologous protein 
expression procedures is the host bacterium Escherichia coli (E. coli) which because it is 
relatively easy to manipulate and economical, yet yields high-levels of recombinant protein 
production, a process commonly known as overexpression137, 138.  A recent review evaluates 
genetic approaches for improvement of plasmid based expression of recombinant protein in E. 
coli139.  Albeit, there are other bacteria which can be used for the same purpose such as 
Lactococcus lactis140 and Bacilli (Bacillus subtilis and Brevibacillus choshinensis)141, 142.  
Other non-E.coli expression systems for heterologous proteins are yeast cell (Kluyveromyces 
lactis, Pichia pastoris, Saccharomyces cerevisiae and Schizosaccharomyces pombe), insect 
cell, mammalian cell and cell-free (CF) expression systems140, 143, 144.  Furthermore, fungi and 
protozoa have been developed as alternative recombinant protein expression systems145.  A 
review on the latest approaches on efficient production of protein for use in drug discovery 
critically evaluates these expression systems146.  Protein expression using E. coli is cost 
effective in that cells can be grown to very high densities within a short period of time in 
inexpensive growth media138.  There are many strains of E. coli which can be used for protein 
expression with peculiar advantages and disadvantages, therefore the choice of the strain is 
governed by the specialty of a strain.  The BL21 (DE3) strain and its derivatives are the most 
popular strains for first expression screen and protein expression in general136.  Common 
challenges associated with recombinant protein expression in E. coli are no or low expression, 
inclusion body formation and protein inactivity which were discussed critically in review136, 
139.  A typical protein expression workflow includes cloning, transformation, plasmid isolation 
clone confirmation through sequencing, induction and cell lysis.  After lysis, a crude mixture 
of proteins is obtained that needs to be purified. 
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1.3.2 Protein purification  
Protein purification principles and applications has been reviewed in several textbooks and 
reviews147-151.  It is a systematic sequence of procedures aimed at isolating the protein of 
interest from a concoction of tissues or cells147.  Purification of protein is important in the 
structure evaluation, function characterization and interaction assessment of the desired 
protein.  Protein purification can be categorized as either preparative or analytical.  Preparative 
purifications are aimed at producing proteins such as biopharmaceuticals, enzymes and 
nutritional proteins for especially for subsequent commercial applications.  In this study 
analytical purification will be performed.  The purpose of producing small amounts of protein 
in research is mainly for identification, quantification, and evaluation of the protein's structure 
and function.  Different purification strategies can be employed based on the physicochemical 
characteristics, size, biological activity and binding affinity of the proteins in the mixture147.  
Chromatography is best applied for the purpose of protein purification152.  There are various 
chromatographic techniques which are based on different exclusion properties.  High 
performance liquid chromatography (HPLC) is a chromatographic technique harnessing high 
pressure to elute solutes by gradient through a column fast, thus limiting diffusion but 
improving resolution147, 153.  Size exclusion chromatography is used to separate protein in 
solution by size through the use of porous gels.  Free-flow electrophoresis, ion exchange 
chromatography and hydrophobic interaction chromatography are chromatographic 
techniques, which separate proteins on the basis of differences in charge or hydrophobicity147, 
152, 153.   
The most widely used protein purification method for recombinant proteins expressed in 
bacteria is affinity chromatography153.  This separation technique is based on molecular 
conformation, and it involves the use of specific resins and it includes immunoprecipitation, 
metal binding chromatography and immunoaffinity chromatography147, 153.  The metal binding 
strategy is a technique in which six to eight histidines are engineered into the N- or C-terminal 
of a protein creating a polyhistidine tag and the protein is made to pass through a column with 
immobilized metal ions such as cobalt or nickel which bind strongly to the tag.  The untagged 
proteins pass freely through the column whereas the tagged protein remains bound to the 
column.  The desired protein is eluted with a chemical which competes for binding to the 
column with the histidine tag such as imidazole147.  There are many challenges involved when 
microbial hosts are harnessed to express recombinant proteins.  These include changes in 
conformation, structural flexibility and stability issues, protein insolubility, low purification 
yields and host cell toxicity136.  However fusion tags coupled with affinity techniques address 
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these challenges of production and purification efficiency150.  Enzymes are such proteins which 
are required to undergo the same treatment for use in biopharmaceutical engineering and 
testing, more specifically for enzyme inhibition assays. 
1.3.3 Enzyme inhibition assays  
In drug discovery target proteins are usually enzymes and inhibitors are generally small 
molecules that bind to the active site, thereby hindering the natural function of the enzyme.  
Competitive inhibitors are molecules which mimic the enzyme substrate and compete for the 
active site of the enzyme.  Non-competitive inhibitors are compounds that can bind to an 
enzyme alongside or without a substrate, thereby changing the conformation of both the active 
site and the substrate154.  The inhibition constant (Ki) is the concentration of inhibitor needed 
for half maximum inhibition and it is an indicator of the potency of an inhibitor.  It is sometimes 
presented as dissociation constant KD or IC50
155.  However, the difference between Ki and IC50 
is that in enzymatic binding especially competitive binding, the inhibitor is competing with the 
substrate for the active site, so the concentration required for a 50 % enzyme activity reduction 
depends on the substrate and how tightly the inhibitor binds to the enzyme.  The IC50 is usually 
greater than the Ki, however in low substrate concentration it tends to equal the Ki154, 155.   
Protein-ligand binding can be evaluated through various experimental techniques with varying 
basis of detection, sensitivity and interaction information output.  Hydrodynamic and 
calorimetric methods of analysis include equilibrium dialysis and rate dialysis; affinity gel 
chromatography; analytical size exclusion chromatography; analytical ultracentrifugation; 
capillary electrophoresis; surface plasmon resonance; electro-optics; x-ray and neutron 
scattering; isothermal titration calorimetry and differential scanning calorimetry156, 157.  
Structural and spectroscopic techniques to study enzyme interactions with inhibitors include 
X-ray crystallography, circular dichroism; various fluorescence methods; mass spectroscopy; 
nuclear magnetic resonance; electron paramagnetic resonance and atomic force microscopy156, 
157.  In this present study, the method that will be considered for evaluating protein-ligand 
binding affinity is ITC which will be introduced and reviewed. 
1.3.3.1 Isothermal Titration Calorimetry 
To understand the structure-function relationship in biomolecules, thermodynamics need to be 
evaluated.  One relevant technique for such evaluation is isothermal titration calorimetry158.  
This is a technique which measures binding of molecules through the detection of heat changes 
in solution.  Several reviews and textbooks have discussed the characteristics, applications, 
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advantages and the challenges of this technique159-166.  When performing this experiment, a 
solution containing the protein is titrated by a solution with the ligand (reactant) to attain heat 
exchange158, 159.  Binding either produces an exothermic or endothermic reaction.  The solution 
is kept at a constant temperature by a thermostat and the reaction is assessed through the amount 
of energy required to maintain the constant temperature.  In ITC, the ligand concentration is 
the independent variable under experimental control.  Data which can be processed and 
analysed from a single titration in ITC include the number of binding sites (g), the 
equilibrium/binding constant (Kb), Gibbs free energy of binding (G), binding enthalpy (H), 
binding entropy (S), and the stoichiometry (n) of binding157-159, 167.  Furthermore, ITC 
experiments reveal information on electrostatic interactions, hydrophobic interactions and the 
type of reaction159.  The advantages of using ITC are (a) high accuracy and duplicability with 
a limited degree of error168; (b) high robustness and responsiveness ranging from 10-2 to 103 
µM169; (c) it is a non-destructive technique with no molecular weight restrictions166. 
Several drug development studies targeting a specific protein have employed the assay170-173.  
It is suggested that ITC is the only technique capable of resolving the entropic and enthalpic 
elements of binding affinity which are paramount in evaluating high-affinity binding ligands157, 
160, 174, 175.  Isothermal titration calorimetry is an important assay to validate computationally 
attained structure-based predictions of binding energies and to establish detailed 
structure/energy correlations.  It is possible to directly compare entropic and enthalpic elements 
between the computational simulations and the experimental if explicit solvation of the protein-





Aims and Objectives 
Aim (Paper 1): 
Computational screening of potential inhibitors against LdtMt5 and validation of the screened 
inhibitors through in vitro experiments. 
Specific objectives of the study (Chapter 2) 
• To perform virtual screening for potential inhibitors of LdtMt5 using computational 
applications 
• To investigate the interactions and binding free energy between LdtMt5 and potential 
inhibitors using Molecular Dynamics (MD) simulations 
• To express, purify and perform inhibition studies on LdtMt5 (Chapter 4) 
Aim (Paper 2) 
To determine a computational model employing Quantum Mechanics technique that explains 
the activity and activation energy of β-lactams against LdtMt5. 
Specific objectives of the study (Chapter 3) 
• To investigate the nature of the transition state structure involved in the mechanism  
• To determine the activation free energies of the mechanism using ONIOM through the 
thermodynamics and energetics of the reaction path 
 
Thesis Outline 
The current project evaluates the computational screening of potent lead compounds against 
LdtMt5 and the mechanism of interaction and experimental validation of screened compounds. 
Chapter 2 outlines the virtual screening of compounds and molecular dynamics simulations 
to determine the calculated binding energies using AMBER 14. 
Chapter 3 outlines the mechanism of action of selected β-lactams against LdtMt5 using 
ONIOM.   
Chapter 4 evaluates the experimental binding thermodynamics of a selected β-lactam 
compound using ITC to validate the computational model.  
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Abstract 
Virtual screening is a useful in silico approach to identify potential leads against various targets.  It is known that 
carbapenems (doripenem and faropenem) do not show any reasonable inhibitory activities against L,D-
transpeptidase 5 (LdtMt5) and also an adduct of meropenem exhibited slow acylation.  Since these drugs are active 
against L,D-transpeptidase 2 (LdtMt2), understanding the differences between these two enzymes are essential.  In 
this study, a ligand-based virtual screening of 12766 compounds followed by molecular dynamics (MD) 
simulations were applied to identify potential leads against LdtMt5.  To further validate the obtained virtual 
screening ranking for LdtMt5, we screened the same libraries of compounds against LdtMt2 which had more 
experimentally reported and calculated binding energies.  The observed consistency between the binding affinities 
of LdtMt2 validates the obtained virtual screening binding scores for LdtMt5.  We subjected 37 compounds with 
docking scores ranging from -7.2 to -9.9 kcal mol-1 obtained from virtual screening for further MD analysis.  A 
final set of compounds (n = 10) from four antibiotic classes with ≤ -30 kcal mol-1 Molecular 
Mechanics/Generalized Born Surface Area (MM-GBSA) binding free energies (ΔGbind) were characterised.  The 
outcome of this study provides insight into the design of potential novel leads for LdtMt5.  
Keywords: Virtual Screening; Molecular dynamics (MD); Mycobacterium tuberculosis (M.tb); L,D-




2.0 Introduction  
The alarming rise of multi and extensively drug-resistant tuberculosis (TB) has become a serious global health 
threat [1].  The emergence of resistant strains is partly due to the poor patient compliance to the extensive treatment 
regimen [2,3].  Thus, the identification of new anti-TB leads, particularly LdtMt5, that can shorten the treatment 
regimen and target the resistant TB strains are urgently needed.  Mycobacterium tuberculosis possess a 
peptidoglycan (PG) layer that encapsulates the cytoplasmic membrane and is essential for cellular growth and 
viability [4].  The peptidoglycan structure of M.tb from a stationary-phase culture revealed a high content (80 %) 
of nonclassical 3→3 cross-links generated by L,D-transpeptidation [5], whereas there classical 4→3 cross-links 
are predominantly formed by the D,D-transpeptidation activity of penicillin-binding proteins (PBPs) during the 
exponential phase of growth [6-9].  L,D-transpeptidases (Ldt) and PBPs are structurally similar [10] and contain 
the catalytic active-site cysteine and serine residues, respectively [11].  Five Ldt paralogues have been identified 
for M.tb, LdtMt1 to LdtMt5.  The reported experimental and theoretical studies revealed that both LdtMt1 and LdtMt2 
can be inactivated by carbapenems, a class of β-lactam antibiotics [6,8,5,12].  The enzymes, LdtMt1 and LdtMt2 
also have distinct functions in vivo [9,5] and it has been shown that LdtMt1 may have a role in adaptation to the 
non-replicative state of the bacilli [5],  while LdtMt2 is essential for virulence in a mouse model of acute infection 
[9].  For M.tb, LdtMt5 is required for properly maintaining cell wall integrity [4] and a more recent study also 
revealed that four L,D paralogues, with the exception of LdtMt3, are active in in vitro peptidoglycan cross-linking 
assays, and that all but LdtMt5 are inhibited by carbapenems [7]. 
The single crystal X-ray structure of the extra-cellular portion of LdtMt5 was recently published [4].  Modest 
enhancement in susceptibility of M.tb to certain carbapenems (doripenem and faropenem) was observed 
presumably due to synthetic lethality, as these β-lactams may inactivate other targets.  Meanwhile, a meropenem-
adduct crystal structure was formed which supports very slow acylation of LdtMt5 over many days.  The structures 
of apo-LdtMt5 and its meropenem-LdtMt5 (Fig. 1) demonstrate that, despite overall structural similarity to LdtMt2, 
the LdtMt5 active site residues are different [4].  
 
Fig. 1 The rendering of MERO-LdtMt5 crystal X-ray structure. Shown is a β-hairpin flap (312-330) and Lc loop 
(338-358) and active site pocket in CPK form [HIS287 (342), THR302 (357), ASN303 (358) and CYS305 (360)] 




The presence of a structurally divergent catalytic site and a proline-rich C-terminal subdomain suggest that this 
protein may have a distinct role in PG metabolism, perhaps involving other cell wall anchored proteins.  Also, 
M.tb lacking a functional copy of LdtMt5 displays aberrant growth, and is more susceptible to killing by osmotic 
shock, select carbapenem antibiotics and crystal violet [4].  The β-lactam and oxazolidinone compounds will most 
likely be able to form covalent bonds with the catalytic cysteine of LdtMt5 probably due to the carbonyl and amide 
functional group in the structural backbone.  Hence, in case any promising inhibitors from the other classes are 
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Fig. 2 2D scaffold structures of (1) β-lactam (2) Diarylquinoline (3) Oxazolidinone (4) Rifamycin (5) Quinolone 
classes of TB antibiotics 
 
Carbapenems gave insignificant binding of LdtMt5 experimentally using isothermal titration calorimetry (ITC).  
Carbapenems are considered the last resort antibiotics to treat resistant bacterial infections in humans [15-22].  
This fact motivated us to perform a virtual screening of five classes of known TB antibiotics (Fig. 2).  Virtual 
screening with both AutoDock Vina and Schrödinger Maestro software programs was performed as a benchmark 
for the automated docking.  Molecular dynamics and binding free energy studies were performed on each of the 
screened compounds from the five classes of anti-TB agents.  To the best of our knowledge, a computational 
model to identify and rank the different anti-TB agents against LdtMt5 has not yet been reported.   
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2.1 Materials and methods 
The following in silico approaches were used to screen five classes of known TB antibiotics (Fig. 2) against 
LdtMt5.  The automated docking process was perfomed using Autodock Vina [23] and Schrödinger Maestro [24] 
programs which implement the quasi-flexible docking method to perform the screening [25].  The docked energies 
followed by visual inspection of the inhibitor pose was performed to ensure the close proximity of the selected 
compounds with the catalytic cysteine.  This was followed by molecular dynamics simulations/MD trajectory 
analyses using CPPTRAJ module [26] implimented in Amber 14 [27] package. 
2.1.1 System preparation 
The 3D crystal structure of the meropenem-bound LdtMt5 (PDB code: 4ZFQ [13]) was retrieved from the Protein 
Data Bank [28].  The missing residues (the β-hairpin flap is missing having the loop LC and the ex-CTSD being 
disordered) [13] of the LdtMt5 enzyme were refined using MODELLER v9.15 [29].  Assignment of the protonation 
states of the enzyme residues at pH = 7 was performed by recalculating the standard pKa values of the titratable 
amino acids using the empirical propKa server [30], similar to a study on LdtMt2 [31].  These protonation states of 
the titratable residues were used for the virtual screening and for the subsequent modelling. 
The chemical compounds used for the screening were retrieved from the ZINC [32] database.  This database is 
available for free download (http://zinc.docking.org) in different formats usable for computational studies [32].  
Compounds from five classes of known TB antibiotics were subjected for the initial screening-based on their 
mode of action.  Each scaffold of the five classes was drawn using the 2D Sketcher tool implemented in ZINC 
GUI.  A structural similarity index of 99 % was set for all compounds except for rifamycin in which ligand mining 
could only be performed at a similarity index of 50 %.  All the screened compounds obeyed  Lipinski’s rule [33] 
of drug-likeness to filter the compound molecules and Veber’s criteria for oral bioavailability of drug candidates 
[34].  The considered Lipinski’s parameters [33] are as follows: molecular weight; xlogP; net charge; rotatable 
bonds; polar surface area; hydrogen donors; hydrogen acceptors; polar and apolar solvation (Table 1). 
 
Table 1 Parameters set for all screened compounds which were subjected to Lipinski’s rules and Veber’s drug-
like filter 
 
Parameter Minimum Maximum 
Molecular weight (g/mol) 32 500 
xlogP -4.00 5 
Net charge -5 5 
Rotatable bonds 0 10 
Polar surface area (Å2) 0 140 
Hydrogen donors 0 5 
Hydrogen acceptors 0 10 
Polar solvation (kcal mol-1) -400 1 
Apolar solvation (kcal mol-1) -100 40 
51 
 
2.1.2 Virtual screening using AutoDock Vina  
AutoDock Vina is a program for molecular docking and virtual screening.  The prepared 3D structure of LdtMt5 
[13] in PDB format was converted to pdbqt format using raccoon [23], likewise the library of compounds 
downloaded from ZINC database in mol2 format were converted to pdbqt format.  Virtual Screening using 
automated docking involves the preparation of the receptor (this includes assigning of Kollman charges [35] and 
Gasteiger partial charges [36] to all atoms and assignment of AD4 types to atoms of the protein structure), ligands 
and a config file in which grid center, a grid box size, and a docking run number are assigned.  AutoDock tools 
1.5.6 [37] were employed to determine the proper size of the grid box for the potential binding site for the lead 
compounds and the receptor grid centre was set on Cys305 (360) (active site reactive residue) [13].  The grid box 
was determined as centre (X = 3.9 Y = -39.5 Z = 12.1) and dimension (X = 45 Y = 45 Z = 45) with the grid 
spacing of 0.375 Å were considered for each of the following atom types: A C H HD N OA and SA representing 
all probable atom types in the target enzyme.  Created finally, was a conf.txt file which includes receptor in pdbqt 
format, a grid center with x, y, z coordinates, a grid box size in Å, and a docking run number of 10.  The virtual 
screening was carried out using the python script, VS.bash executable on AutoDock Vina.  Docked results were 
ranked based on the binding affinities and visual inspection to ensure an acceptable drug/enzyme interaction is 
present.  Visual inspection of the selected ligands inside the enzyme was performed using the Discovery Studio 
[38] software program. 
2.1.3 Virtual screening using Schrödinger Maestro 
Schrödinger Maestro software program was applied for the docking studies.  Protein/ligand preparation and virtual 
screening were all performed in the Maestro 11.2 graphical user interface [24].  The Protein Preparation Wizard 
[39] of the Schrödinger Maestro software program was used to prepare the 3D protein structure.  The pre-
processing of the protein was performed which includes assigning of bond orders; adding of hydrogens; creating 
zero-order bonds to metals; creating disulphide bonds; deleting crystallographic waters beyond 5.00 Å from hetero 
groups and generating hetero states using Epik[40]:  pH 7.0+/-2.0.  In the 3D protein structure refinement, the 
alignment of H-bonds was done using PROPKA pH: 7.0 and waters with less than three hydrogen bonds to non-
waters were removed.  Restrained minimization was performed to converge heavy atoms to RMSD of 0.30Å. 
The 2D compound sketches were imported onto the Schrödinger Maestro project table and they were converted 
into a 3D model using the pre-set option.  The LigPrep module [24] was used to refine the structures using default 
parameters.  Ionization was performed to generate possible states at target pH:7.0+/-2.0 using Epik [40] and 
tautomers were generated.  The compounds were subjected to OPLS3 [41] (optimized potentials for liquid 
simulations) force field for energy optimisation.  For ligand preparation, the system was set to retain specified 
chiralities to 10 per ligand and the output format was Maestro from Schrödinger software program.  The grid box 
was positioned at the centre and the receptor grid centre was set on Cys305 (360) (active site reactive residue) 
[13] with grid spacing minimum distance of 1 Å and maximum distance of 3.5 Å.  The XYZ coordinates were -
31.88; 23.5 and -46.48 respectively.  Default settings of Maestro 11.2 were used for other parameters such as 
constraints, rotatable groups, and sites. 
Using a predetermined receptor grid, quasi-flexible docking [14,42,25] was performed via the Glide [43] mode of 
Schrödinger Maestro (Schrödinger, Inc).  The system was set to resume post-docking minimization, setting the 
number of poses per ligand to 5.  For filtering, default settings were employed and this includes applying the Epik 
52 
 
state penalty parameters [24] for docking and the scaling of ligand van der Waals radii for nonpolar atoms using 
the scaling factor 0.80 [44,45] and partial charge cut-off 0.15 [45,44].  Ligand docking was done using the three 
incremental stages of ranking accuracy i.e. high throughput virtual screening (HTVS), Glide simple precision (SP) 
and Glide extra precision (XP) [24].  The docking score (Glide GScore) from Glide extra precision (XP) was used 
to evaluate specific protein-ligand interactions within the active site of the enzyme.  
The difference with these programs lies in the docking algorithm in which Schrödinger Maestro uses the Glide 
module which employs the Monte Carlo algorithm [46] that makes random moves and accepts or rejects each 
conformation based on Boltzmann probability while AutoDock Vina utilizes the AutoDock module.  This program 
applies the genetic algorithm [47], which maintains a selective pressure towards an optimal solution, with 
randomized information exchange permitting exploration of the search space [25].  However, both software 
modules (Glide and AutoDock) identify multiple top-ranked docked poses per ligand.  They both use hierarchical 
algorithms that are an exhaustive systematic search for the best ligand conformations within the protein active 
site, therefore visual inspection for one best conformation per ligand, based on known interactions was performed 
to identify a single best conformation per ligand for MD simulations. 
2.1.4 Molecular dynamics simulation 
MD simulations were performed to investigate the stability and dynamics of the complexes using the AMBER 14 
package.  The ff99SB [48] force field was used to describe the protein-ligand interactions whereas the general 
AMBER force field (GAFF) [49] was used to describe solvent-ligand interactions.  System solvation for the 
complexes was performed in a 10 Å cubic box by using TIP3P water model.  To neutralize the system negative 
value, sodium ions were added accordingly.  The protein-ligand complexes were parametrized by the Leap [49] 
module of Amber14 package using the GAFF force field.  All simulations were performed using a 2 fs timestep 
(based on a study with similar protein size) and the rest of the process was also based on the same study [31].  The 
partial Mesh Ewald (PME) [50] summation method was used to calculate the electrostatic forces with space cut-
off of 12 Å.  Using the SHAKE algorithm [51] all bonds were constrained to hydrogen (H) atoms.  A two-stage 
energy minimization process, which is characterised by 2500 steps of steepest decent minimization and 2500 steps 
of conjugated gradient was carried out to get rid of steric clashes.  The solute molecule was first restrained at 500 
kcal mol-1 whereas the water molecules and the ions were relaxed.  The harmonic restraint was removed on the 
second stage thus the whole system was relaxed.  Heating of the system to a constant temperature of 300 K 
followed with a restraint of 10 kcal mol-1 for 200 ps, to keep the solute fixed.  Density equilibration for 50 ps was 
performed and MD simulations ran at a constant temperature and pressure (1 atm).  The LdtMt5-ligand complexes 
were simulated for 20 ns [52].  The post-dynamics trajectory analysis including radius of gyration (Rg) and root 
mean square deviation (RMSD) was evaluated.  In addition to that, triplicate MD simulations were also performed 




2.1.5 Binding free energy calculation 
MM-GBSA is a widely accepted method to compare the binding affinities and to gain rational insights about 
inhibitors by analysing the binding mechanism [53].  The average binding free energies (ΔGbind) of the protein-
ligand complexes was calculated for the last 10 ns using MM-GBSA method [54].  Counter ions and water 
molecules were removed.  Entropy penalty (-TΔS) for the complexes was obtained using normal mode analysis 
(nmode).  The PTRAJ and CPPTRAJ modules [26] were used to analyse the MD trajectories.  
2.2 Results and discussions  
2.2.1 Data set preparation  
A total of 12766 antibacterial lead compounds in five categories listed in Table 2 were derived from ZINC 
database were screened.  
Table 2 The selected five categories of antibacterial compounds from ZINC database 
Class Mode of action Number of screened 
compounds  
β-lactam Cell wall biosynthesis (inhibition of transpeptidase 
and inhibition of β-lactamase by clavulanic acid) 
2707 
Diarylquinoline ATP synthesis inhibition (subunit c of ATP 
synthase) 
4309 
Oxazolidinone Protein synthesis inhibition 3065 
Rifamycin RNA synthesis inhibition (inhibition of RNA 
polymerase). 
2678 







2.2.2 Ligand-based virtual screening and docking 
Structural parameters were set to filter the compounds for screening based on Lipinski’s rule-of-five (Table 1).  
Virtual screening of ligands was performed on a  set of 98 docked poses and then considered for further visual 
inspection of the interaction [14] to determine the optimal ligand conformation per compound in the active pocket 
of LdtMt5.  A total of 46 top-ranked poses was obtained using AutoDock Vina, (Table 3) and 52 from Schrödinger 
Maestro (Table 4). From there a total of 37 compounds, (13 from AutoDock Vina, Table 3 and 24 from 
Schrödinger Maestro Table 4), were selected for further MD analysis.  Fig. 3 shows the virtual screening 
workflow down to the final 10 lead compounds. 
 
 
Fig. 3 Virtual screening workflow to the ten final lead compounds  
The docking (consensus) scores for AutoDock Vina of the 10 top-ranked compounds across all classes lie between 
-7.4 and -9.0 kcal mol-1 (Table 3).  The Schrödinger Maestro top-ranked docking scores were also considered, 
and the values are between -7.2 and -9.9 kcal mol-1 (Table 4).  The docking scores of both software programs 




Table 3 The top 10 ligands per class based on the lowest docked energies were chosen for AutoDock Vina against 
LdtMt5 (The optimal ligands in the active pocket, highlighted in blue, were selected for further MD analysis) 
Antibiotic class Ligand Identity Docking score (kcal mol-1) 
β-lactam 
1 ZINC 01662030 -8.4 
2 ZINC 02475683 -8.4 
3 ZINC 02475684 -8.4 
4 ZINC 01662029 -8.3 
5 ZINC 02462884 -8.3 
6 ZINC 03791246 -8.3 
7 ZINC 01412853 -8.3 
8 ZINC 01385054 -8.2 
9 ZINC 01412838 -8.2 
10 ZINC 01412839 -8.2 
Rifamycin 
1 ZINC 19569373 -8.6 
2 ZINC 03197606 -8.4 
3 ZINC 14828615 -8.4 
4 ZINC 01551761 -8.4 
5 ZINC 13125731 -8.2 
6 ZINC 13125732 -8.2 
7 ZINC 14693083 -8.2 
8 ZINC 15216498 -8.2 
9 ZINC 33832153 -8.2 
10 ZINC 39227187 -8.2 
Oxazolidinone 
1 ZINC 03921583 -8.7 
2 ZINC 03921580 -8.5 
3 ZINC 00586642 -8.4 
4 ZINC 00003190 -8.3 
5 ZINC 00594969 -8.3 
6 ZINC 03785925 -8.3 
7 ZINC 03921504 -8.3 
8 ZINC 05774946 -8.2 
9 ZINC 03791902 -8.2 
10 ZINC 03921352 -8.2 
Diarylquinoline 
1 ZINC 00022457 -9.0 
2 ZINC 00022456 -8.7 
3 ZINC 00057310 -8.2 
4 ZINC 00075863 -8.2 
5 ZINC 00097351 -8.2 
6 ZINC 00152025 -8.2 
7 ZINC 00236246 -8.1 
8 ZINC 00254016 -8.1 
9 ZINC 00118842 -8.0 
10 ZINC 00192295 -8.0 
Quinolone 
1 ZINC 80595608 -8.0 
2 ZINC 80595598 -7.9 
3 ZINC 80595612 -7.9 
4 ZINC 78317542 -7.6 
5 ZINC 80595606 -7.6 
6 ZINC 79236395 -7.4 
AutoDock Vina top-ranked docking scores were considered, and the values are between -7.4 and -9.0 kcal mol-1 
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Table 4 The Schrödinger Maestro top ligands per class based on the lowest Glide docking score against LdtMt5 
(The optimal ligands in the active pocket, highlighted in blue, were selected for further MD analysis) 
Antibiotic class Ligand Identity Docking score (kcal mol-1)  
β-lactam 















2 ZINC 03788344 
3 ZINC 03788344 
4 ZINC 03788344 
5 ZINC 03808350 
6 ZINC 03788344 
7 ZINC 03808351 
8 ZINC 03808352 
9 ZINC 03826440 
10 ZINC 03826440 
11 ZINC 03788344 
12 ZINC 03785001 
13 ZINC 03785029 
14 ZINC 03808350 
15 ZINC 03784242 
Rifamycin  












2 ZINC 06483423 
3 ZINC 06483425 
4 ZINC 06483423 
5 ZINC 13532137 
6 ZINC 59077219 
7 ZINC 59077220 
8 ZINC 59077221 
9 ZINC 59077222 
10 ZINC 59077219 
11 ZINC 59077220 
12 ZINC 59077221 
Oxazolidinone  














2 ZINC 00108966 
3 ZINC 00108973 
4 ZINC 00108973 
5 ZINC 00108966 
6 ZINC 00108966 
7 ZINC 00108973 
8 ZINC 00108973 
9 ZINC 00052567 
10 ZINC 00052568 
11 ZINC 02512954 
12 ZINC 02512954 
13 ZINC 00108966 
14 ZINC 00108966 
Diarylquinolone  










2 ZINC 00002447 
3 ZINC 00002447 
4 ZINC 00007109 
5 ZINC 00060410 
6 ZINC 00060410 
7 ZINC 00060410 
8 ZINC 00060410 
9 ZINC 00060410 
10 ZINC 00060410 
Quinolone  
1 ZINC 80595598 -3.6 
Schrödinger Maestro top-ranked docking scores were considered, and the values are between -7.2 and -9.9 kcal 





2.2.3 Binding free energy analysis 
Our group has reported that MD studies provide comparable binding free energies for LdtMt2 with several 
inhibitors [31] to experiment.  Based on the calculated docking scores, the complexes showing the best score and 
best ligand conformations within the protein active site were subjected to further molecular dynamics simulations 
using the AMBER14 package. Similar protocol was carried out by John et al. and Islam et al. [52,55].  With a 
cut-off predicted binding energy (ΔGbind) of ≤ -30 kcal mol-1, a final set of lead compounds (n = 10) (marked in 
bold) from four antibiotic classes was selected from Tables 5 and 6.  
Table 5 Binding free energies and their corresponding components for compounds against LdtMt5 screened by 
AutoDock Vina using the AMBER14 package 
ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation  -TΔS ΔGbind 
β-lactam 
02475683 -59.68 -9.72 -69.41 27.7 -6.82 20.88 -31.01 -48.52 
02462884 -54.07 -8.97 -63.03 22.7 -6.42 16.28 -27.53 -46.75 
03791246 -26.26 -123.11 96.85 -112.62 -3.1 -155.72 -18.6 -18.86 
Rifamycin 
14693083 -42.27 -5.81 -48.07 22.49 -3.97 18.52 -2.03 -29.95 
13125732 -30.71 -7.55 -38.26 18.27 -2.96 15.31 -15.55 -22.95 
13125731 -28.75 -5.52 -34.27 19 -2.92 16.09 -20.68 -18.18 
Oxazolidinone 
05774946 -30.17 -0.5 -30.67 8.68 -3.93 4.75 -20.58 -25.92 
00003190 -32.67 -4.89 -37.57 15.9 -3.39 12.51 -17.07 -25.06 
00594969 -26.73 -0.41 -26.32 9.77 -3.14 6.63 -3.58 -19.7 
Diarylquinolone 
00022456 -47.08 -4.08 -51.15 -14.65 -5.36 9.28 -18.42 -41.87 
00022457 -44.53 -5.72 -50.25 -16.46 -5.01 11.45 -23.61 -38.8 
00192295 -35.19 -2.46 -37.65 14.48 -3.22 11.26 -21 -26.39 
Quinolone 
78317542 -30.55 -278.11 -308.64 290.44 -3.91 286.52 -18.06 -22.12 
79236395 -31.66 -154.13 -185.77 167.67 -3.79 163.88 -14.87 -21.89 
Compounds in bold are the best binders within the -30 kcal mol-1 ≤ screening threshold and compounds in normal 
text are below the threshold  
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Table 6 Binding free energies and their corresponding components for compounds screened by Schrödinger 
Maestro using the AMBER14 package 
ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation -TΔS ΔGbind 
β-lactam 
03784242 -28.18 -154.51 -182.69 160.28 -4.08 156.20 -21.11 -26.49 
03785029 -27.18 -153.7 -180.88 159.8 -4.03 155.77 -24.48 -25.11 
03785344 -19.65 -333.09 -352.74 339.3 -3.43 335.87 -18.24 -16.87 
03785001 -30.57 -175.27 -205.83 179.63 -4.48 175.15 -16.06 -30.68 
03808350 -30.12 -136.81 -166.93 150.41 -4.72 145.69 -19.04 -21.23 
03808351 -33.59 -188.02 -221.61 191.16 -4.87 186.29 -27.84 -35.32 
03808352 -34.38 -167.3 -201.68 174.86 -5.36 169.5 -26.19 -32.18 
03826440 -26.83 -176.63 -203.45 184.25 -4.36 179.9 -18.32 -23.56 
Rifamycin 
06483423 -37.88 -10.71 -48.59 26.03 -4.57 21.45 -17.91 -27.14 
06483425 -39.5 -11.34 -50.85 27.31 -4.77 22.53 -11.67 -28.31 
13532137 -46.38 -12.24 -58.62 26.57 -5.16 21.41 -19.39 -37.21 
59077219 -9.81 -98.27 -108.1 103.06 -1.73 101.34 -14.14 -6.77 
59077220 -17.38 -173.77 -191.17 176.93 -3.29 173.64 -22.4 -17.53 
59077221 -20.37 -92.93 -113.32 104.55 -3.23 101.32 -17.38 -11.99 
59077222 -33.2 -164.92 -196.14 176.58 -4.28 172.3 -22.59 -23.84 
Oxazolidinone 
00052567 -26.43 -304.35 -330.78 315.3 -4.06 311.24 -22.5 -19.54 
00052568 -32.74 -307.5 -340.24 316.29 -4.38 311.91 -9.02 -28.33 
00108966 -30.59 -4.15 -34.74 12.44 -3.84 8.6 -18.77 -26.13 
00108973 -43.19 -3.93 -47.12 14.93 -5.02 9.91 -23.21 -37.21 
02512954 -21.99 -331.59 -353.58 332.66 -3.29 329.37 -20.23 -24.21 
Diarylquinolone 
00002447 -44.45 -257.63 -302.08 270.09 -5.69 264.4 -22.68 -37.68 
00007109 -22.67 -3.16 25.83 -3.16 12.22 9.45 -20.51 -16.38 
00060410 -28.61 -4.13 -32.74 12.17 -3.48 8.69 -14.97 -24.05 
00096619 -34.15 -4.99 -39.13 15.42 -4.18 11.24 -15.17 -27.89 
Compounds in bold are the best binders within the -30 kcal mol-1 ≤ screening threshold and compounds in normal 
text are below the threshold 
 
Two different classes of compounds were obtained as the best binders from utilizing the two docking programs.  
AutoDock Vina identified two lead compounds in terms of highest binding, both monobactams and these 
compounds showed greater predicted binding energies compared to the three carbapenems which were identified 




Table 7 Identified lead compounds with their antibacterial class, ZINC ID, calculated binding energies and the 
corresponding chemical structure, ten in total 
Class ZINC ID ΔGbind (kcal mol−1) Structure 



















Oxazolidinone 00108973 -37.21 
 
Rifamycin 13532137 -37.21 
 
Compounds in bold were screened by AutoDock Vina [23] and compounds in normal text were screened by 




The final set of compounds (n = 10) had all parameters within the Lipinski’s and Veber’s constraints of drug-
likeness (Table 8).  It is noteworthy that all the screened compounds revealed a topological polar surface area 
(tPSA) > 150 Å2, which is an indication of a high bioavailability [56].  
Table 8 Drug-like properties of the 10 potential leads from the ZINC database 
Compounds in bold were screened by AutoDock Vina and compounds in normal text were screened by 
Schrödinger Maestro. Representations: * β-lactam; ˠ Diarylquinolone; ˟ Oxazolidinone; ʱ Rifamycin 
 
In light of the experimentally reported covalently bound interactions between L,D-transpeptidases and β-lactams, 
the subsequent section of this study focuses on better understanding of the binding interactions between the β-
lactam class and LdtMt5.  To validate the virtual screening ranking and to compare the binding affinities, selected 
carbapenems known to inhibit LdtMt2 were screened for both LdtMt2 and LdtMt5 (Table 9).  According to the 
consistent trend observed in Table 9, the docking scores obtained seem to be valid. 
Table 9 Comparison of the calculated binding energies for carbapenems on LdtMt5 against the calculated and 
experimental [57,58] binding energies for LdtMt2 




LdtMt5 ΔGdocked  
(kcal mol-1) 
Biapenem -9.0[57] -6.7 -6.2 
Imipenem -9.8[58] -6.5 -5.5 
Meropenem -8.2[58] -7.1 -6.3 
Tebipenem -9.4[57] -6.6 -6.0 
The ZINC IDs for biapenem, imipenem, meropenem and tebipenem are 03784073, 03830927, 03808779 and 
04072129 respectively 
  



















*02475683 4.37 11.33 -14.54 0 10 0 124 489.415 4 
*02462884 4.53 12.58 -14.66 0 8 0 105 445.406 4 
*03808351 -0.76 -8.64 -92.33 4 7 0 117 342.417 5 
*03808352 -0.76 -8.61 -86.43 4 7 0 117 342.417 5 
*03785001 4.73 1.62 -34.23 1 3 1 24 384.371 4 
ˠ00022456 4.06 1.31 -14.65 0 5 0 64 324.343 2 
ˠ00022457 4.49 1.62 -14.46 0 5 0 64 338.37 2 
ˠ00108973 0.69 -1.15 -18.45 1 6 0 67 267.329 4 
˟00002447 1.43 -1.02 -53.74 4 6 1 96 333.408 7 
ʱ13532137 0.92 -3.03 -13.32 5 7 0 127 318.281 2 
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2.2.4 Trajectory analyses of β-lactam-LdtMt5 complexes 
2.2.4.1 Root mean square deviation (RMSD) analysis 
RMSD is a measure of accuracy, comparing the differences between predicted values and observed values of a 
model [59].  The average values of the β-lactam-LdtMt5 complexes (A-E) (Fig. 4) are 1.88, 1.75, 1.35, 2.25 and 
1.55 Å respectively which lies in the accepted range of <2.5 Å [14] for stable simulation.   
 
Fig. 4 Time evolution of the root mean square deviation (RMSD) of the β-lactam- LdtMt5 complexes of A 
02475683-LdtMt5 (black), B 02462884-LdtMt5 (red), C 03808351-LdtMt5 (green), D 03808352-LdtMt5 (blue) and E 




2.2.4.2 Analysis of the radius of gyration (Rg) 
The radius of gyration is defined as the moment of inertia of the C-α atoms from its centre of mass and it is used 
as an indicator of structural compactness of the protein-ligand complex [60,61].  Fig. 5 shows the Rg plots for the 
β-lactam-LdtMt5 complexes over a 20 ns trajectory.  The average Rg values for complex A (02475683-LdtMt5), B 
(02462884-LdtMt5), C (03808351-LdtMt5), D (03808352-LdtMt5) and E (03785001-LdtMt5) reveal great overal 
similarity.  The values are 29.65 Å, 29.60 Å, 29.83 Å, 30.25Å and 29.60 Å respectively. 
 
Fig. 5 The radius of gyration (Rg) of the β-lactam-LdtMt5 complexes of A 02475683-LdtMt5 (black), B 02462884-
LdtMt5 (red), C 03808351-LdtMt5 (green), D 03808352-LdtMt5 (blue) and E 03785001-LdtMt5 (yellow) during 20 
ns MD trajectories  
 
2.2.4.3 Binding free energy (∆Gbind) analysis of β-lactam-LdtMt5 complexes 
In this study, the calculated binding energies of β-lactam derivatives (meropenem and imipenem) against LdtMt2 
from previous studies [62,31] were used to validate the selection of lead compounds which demonstrated the best 
binding affinity for LdtMt5.  We hereby calculated the binding free energies (∆Gbind) of the selected β-lactam-LdtMt5 
complexes using the MM-GBSA method by extracting 1000 snapshots at 10 ps interval from the last 10 ns 
production MD trajectories.  The entropy (-TΔS) contributions were calculated using normal mode analysis 
[63,64] by extracting 100 snapshots from the MD trajectories.  The contributing binding components upon 
complexation, namely, ΔEvdw, ΔEele, ΔGgas, ΔGpolar, ΔGnonpolar and ΔGsolvation are shown in Table 10.  The results 
reveal binding free energies (∆Gbind) of -48.52 kcal mol-1 and -46.75 kcal mol-1 for complex A (02475683-LdtMt5) 
and complex B (02462884-LdtMt5) respectively.  The binding free energies of complexes C (03808351-LdtMt5), D 
(03808352-LdtMt5) and E (03785001-LdtMt5) are -35.32 kcal mol-1, -32.18 kcal mol-1 and -30.68 kcal mol-1, all 
between -30 kcal mol-1 and -40 kcal mol-1.  It was observed that compounds with a greater binding affinity (A and 
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B) are characterised by a more negative van der Waals value and they are less electronegative as compared to the 
other compounds (C-E). 
Table 10 Calculated binding free energies and their corresponding components for the selected β-lactam-LdtMt5 
complexes using the AMBER14 package 
Compound ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation -TΔS ΔGbind 
A 02475683 -59.68 -9.72 -69.41 27.7 -6.82 20.88 -31.01 -48.52 
B 02462884 -54.07 -8.97 -63.03 22.7 -6.42 16.28 -27.53 -46.75 
C 03808351 -33.59 -188.02 -221.61 191.16 -4.87 186.29 -27.84 -35.32 
D 03808352 -34.38 -167.3 -201.68 174.86 -5.36 169.5 -26.19 -32.18 
E 03785001 -30.57 -175.27 -205.83 179.63 -4.48 175.15 -16.06 -30.68 
Compounds in bold were screened by AutoDock Vina and compounds in normal text were screened by 
Schrödinger Maestro   
2.2.4.4 Residue-inhibitor interaction analysis 
To further elucidate the possible intermolecular hydrogen bonding and electrostatic interactions between β-
lactam-LdtMt5 complexes, we used LigPlot program [65].  The active site of LdtMt5 is defined by four conserved 
residues (His287 (342), Thr302 (357), Asn303 (358) and Cys305 (360)) [13].  Fig. 6 shows the schematic 
representations of core amino acid residues interaction modes between the β-lactam compounds (A-E) and LdtMt5.  
It is important to note that the residue-inhibitor interaction of compound A with LdtMt5 demonstrates close 
hydrogen bond interaction between the ligand and two active site residues Asn303 (358) and Cys305 (360), which 
can be a possible explanation to the highest binding free energy observed.  Compound B interact with the residue 
Asn263 (318) and a water molecule which is within the active site (Fig. 6) and binding free energies (Table 10) 
of both compounds (A, B) are within the same range.  Common among all 3 compounds (C-E) is the interaction 
with residue Arg242 (297).  Compound C has other interactions with residues Glu284 (339) and Gly304 (359).  
Val244 (299) is a common residue between compound D and E while each compound interacts with Gly304 (359) 
and Asn243 (298) respectively.  The other 3 compounds (C-E) also fall in a similar binding free energies range 





Fig. 6 2D schematic representations of the hydrogen and hydrophobic interactions between LdtMt5 residues and 
the selected β-lactam compounds, ZINC ID (A) 02475683, (B) 02462884, (C) 03808351, (D) 03808352, and (E) 
03785001.  All structures are average conformations generated from the last 10 ns snapshots of each MD system 
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Results from virtual screening and docking studies demonstrated that several lead compounds from different 
classes of antibiotics potentially tend to bind to the active pocket of LdtMt5.  The binding free energies also 
demonstrate favourable binding potential of our lead compounds to LdtMt5.  It is known that β-lactams, specifically 
carbapenems, form covalent bonds with the catalytic cysteine (305) residue of LdtMt5 due to the carbonyl 
functional group in the structural backbone.  However, results from the model as highlighted by the residue-
inhibitor interaction analysis seem to suggest that other compounds may interact differently with LdtMt5.  Instead 
of forming covalent interaction, other potential inhibitors of LdtMt5 may perform competitive inhibition instead.  
It is also important to note that the closer the inhibitor interacts with the active site residues, the higher the binding 
affinity it may have as demonstrated compound A (Fig. 6). 
2.3 Conclusion 
In this study, virtual screening of compounds from ZINC database against LdtMt5 was investigated with AutoDock 
Vina and Schrödinger Maestro software programs.  The obtained docking scores presented a reasonable number 
of lead compounds which can be utilised as potential drug candidates against LdtMt5.  Despite the lack of overlap 
on the screened compounds using these two different software programs, both provided reasonable binding scores.  
The observed exclusiveness of each program to a certain class of compounds strongly suggests that the 
effectiveness of a computational technique is subject to the software program utilised.  To improve the chances 
of getting a ‘lead compound’, different programs with alternative search algorithms need to be employed for the 
screening of compound libraries.  It is essential to verify virtual screening results with MD free energy calculations 
as was demonstrated before [14].  The screened lead compounds were subjected to MM-GBSA approach.  A final 
set of compounds (n = 10) from four antibiotic classes with ≤ -30 kcal mol-1 were obtained. 
The computational model presented in this study is robust in that its accuracy was validated on both the docking 
stage as well as on the MD simulations stage.  Such benchmarking offers baseline comparisons of experimental 
and computational data from a paralog of the enzyme under study which brings about comparable extrapolations 
applicable to the natural system.  The model as expressed through the docking affinities and binding energy 
calculations from MD simulations, demonstrated strong binding ligands.  It should also be noted however, that 
the residue-inhibitor interaction analysis further revealed that apart from the already known interactions, other 
compounds interact with other active site residues of the target.  This certainly paves way to explore other β-
lactam binding mechanisms and expresses the importance of molecular dynamics simulations in revealing other 
possible interactions within the active site of other transpeptidases.  We therefore conclude that pharmacophore 
based virtual screening and molecular dynamics simulations are essential tools which will continue to play a 
significant role in drug design and identification of novel ligands.   
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Abstract 
Tuberculosis (TB) is one of the world’s deadliest diseases caused by the bacterium, 
Mycobacterium tuberculosis (M.tb).  The L,D-transpeptidase enzymes catalyze the most 
dominant 3→3 peptidoglycan cross-links of the M.tb cell wall and specific β-lactam antibiotics 
have been reported to inhibit its action.  Carbapenems inactivate L,D-transpeptidases (LDTs) 
by acylation, although differences in antibiotic side chains modulate drug binding and acylation 
rates.  Herein, we used a two-layered our Own N-layer integrated Molecular Mechanics 
ONIOM method to investigate the catalytic mechanism of L,D-transpeptidase 5 (LdtMt5) by β-
lactam derivatives.  LdtMt5 complexes with six β-lactams, ZINC03788344 (1), ZINC02462884 
(2), ZINC03791246 (3), ZINC03808351 (4), ZINC03784242 (5) and ZINC02475683 (6) were 
simulated.  The QM region (high-level) comprises the β-lactam, one water molecule and the 
Cys360 catalytic residue, while the rest of the LdtMt5 residues were treated with AMBER force 
field.  The activation energies (ΔG#) were calculated with B3LYP, M06-2X and ωB97X 
density functionals with 6-311++G(2d, 2p) basis set.  The ∆G# for the acylation of LdtMt5 by 
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the selected β-lactams, were calculated as 13.67, 20.90, 22.88, 24.29, 27.86 and 28.26 kcal mol-
1 respectively.  Several of the compounds showed an improved ∆G# when compared to the 
previously calculated for imipenem and meropenem for the acylation step for LdtMt5.  This 
model provides further validation of the catalytic inhibition mechanism of LDTs with atomistic 
detail.  
Keywords: Mycobacterium tuberculosis (M.tb), L,D-transpeptidase 5 (LdtMt5), QM/MM, 
ONIOM, Catalytic mechanism. 
3.0 Introduction 
The understanding of the enzyme-catalysed reactions mechanisms is essential to the study of 
biochemical processes.  Possibly, an improved understanding can add to the development of novel 
inhibitors with greater therapeutic potential[1].  In M.tb peptidoglycan is required for major cell 
division, growth and recovery from dormancy.  This is a metabolically inactive state that allows 
the mycobacterium to endure hostile physical-chemical situations or nutrient 
malnourishment[2].  This inactive state subsequently leads to latent infection which affects 
one-third of world’s population[2].  The β-lactam antibiotics, an effective therapeutic category 
of antibacterial[3] agents for the inhibition of transpeptidases, which are required in cell wall 
biosynthesis[4].  Majority of the cross-linkage has been reported to occur via 3→3 linkages 
catalysed by L,D-transpeptidases which bypass the D,D-transpeptidase activity of penicillin-
binding proteins (PBPs), leading to high-levels of resistance to the drugs[5-8].  The second 
type of cross-linkage occurs via 4→3 linkages catalysed by D,D-transpeptidase (also PBPs).  
This group of antibacterial drugs inactivate both transpeptidase enzymes[2, 3, 5, 9-12].  
Carbapenems are one group of β-lactam antibiotics showed to have inactivated L,D-
transpeptidase activity[2, 5, 10-12].  As is the case for all cysteine proteases[13], L,D-
transpeptidases hydrolyse the peptide bonds by two catalytic processes that are required to start 
enzyme acylation by the second last peptide of the donor stem leading to the release of the C-
terminal residue.  This is tailed by deacylation of this acyl-enzyme intermediate by an acceptor 
stem[10, 14].   
Unique to M.tb, the majority of the cross-links are generated by L,D-transpeptidation reaction, 
making this enzyme essential in the adaptation of M.tb to the stationary phase[5].  Combined 
inhibition of both transpeptidases (L,D and D,D) will permanently hinder the synthesis of the 
peptidoglycan sheet and therefore, destroy the bacteria[15].  Erdemli and co-workers[10] 
proposed mechanism of acylation of L,D-transpeptidase to be built on cysteine protease 
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mechanism.  This mechanism for LdtMt2 proceeds in two phases.  Firstly, is the acylation step, 
where the Cys352 thiolate is produced via abstraction of proton bonds on the acyl carbon of 
the substrate resulting in a tetrahedral intermediate.  Secondly, in the deacylation step, 
additional peptide stem goes into the catalytic pocket, and binds to the residues with the side 
chain amide of the m-A2pm3′ residue.  In this step, His336 plays the role of the catalytic base 
via abstraction of a proton from the amine group of the mA2pm3′ residue, which in turn makes 
an attack (nucleophilic) on the carbonyl carbon of the acyl-enzyme[10]. 
Computational applications has been employed to investigate this mechanism, which 
corroborates experimental observations for the catalytic mechanism of L,D-transpeptidase 2, a 
commonly studied enzyme from M.tb[16, 17].  The first computational study on the inhibition 
mechanism of L,D-transpeptidase 2 was carried out using a hybrid DFTB/MM potential[16].  
The peptidoglycan fragment bound with the initial coordinates of the extramembrane portion 
of LdtMt2  (ex-LdtMt2) (PDB code: 3TUR) was replaced in silico, for the natural substrate.  Based 
on the results obtained, the formation of His336-imidazolium/Cys354-thiolate initiated a four-
membered ring acylation step.  This is then followed by a single step attack of Cys354 on the 
carbonyl carbon of the substrate. The aforementioned is the rate-limiting step, and it agrees 
with the experimental results for cysteine proteases.  The attack on the acyl-enzyme complex 
by amine group of the subsequent substrate and results in the formation of  3→3 peptide bond 
(deacylation step) [16].  Fakhar et al.[17] using a β-lactam model investigated the acylation of 
β-lactam ring by LdtMt2 in M.tb with B3LYP/6-31 + G(d).  The acylation mechanism employed 
four-membered and six-membered ring transition states.  The calculated thermochemical 
quantities for the proposed models specified that the activation free energy for the six-
membered ring transition states model was significantly lower in comparison to other 
models[17]. 
The crystal structure of LdtMt5 was recently solved both for apo (PDB code: 4Z7A[12]) and 
meropenem bound (PDB code: 4ZFQ[12]).  Any M.tb strain with a deletion of LdtMt5, displays 
abnormal growth phenotype and is more vulnerable to killing by cell wall perturbing agents 
including carbapenems which are considered the last resort antibiotics to combat resistant 
bacterial infections in humans[12].   
Herein we have investigated the acylation reaction of some selected β-lactam derivatives from 
our on-going virtual screening against LdtMt5 via a 6-membered ring mechanism.  These results 
we hope will provide a reasonable computational model for designing of new anti-tuberculosis 
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drugs.  This present work will adopt the protocol reported by Fakhar et al.[17].  The selected 
β-lactams are shown in Fig. 1.  A water molecule will be evaluated as well as the active pocket 
of LdtMt5 at the quantum mechanical (QM) level, and the other portion of the enzyme at 
molecular mechanics (MM) level.  Compounds 1, 3, 4 and 5 are carbapenems while compounds 




























































Fig. 1. 2D structures of the selected β-lactam derivatives  
3.1 Computational methods  
A 6-membered ring transition state mechanism[18, 19] for the acylation of carbapenems by 
LdtMt5 (from M.tb) was investigated with a water molecule within the active pocket.  QM/MM 
(ONIOM[20]) method calculations were applied.  The influence of catalytic water has been 
reported to play a vital role in enzymatic reactions[17] using ONIOM method[20].   
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3.1.1 System preparation  
The crystal structure of meropenem bond (PDB code: 4ZFQ, 2.8 Å resolution)[12] was 
retrieved from RCSB PDB[21]  (Fig. S1) and complexed with the selected β-lactam derivatives 
from ZINC database[22] as described in our on going virtual screening study.  The catalytic 
water molecule was manually inserted at the active site and was constrained (Modred) at a 
sufficiently close distance for a nucleophilic attack to occur[23].  We, therefore, took these 
complexes and performed  partial and full geomtric minimizations using parm99 force field to 
remove clangs and bad connections.  The partial minimization was performed for counterions 
water and molecules only, where the protein was fixed in a 10 Å box.  In the full minimization, 
all atoms were geometrically optimized.  A suitable snapshot from the minimization stage was 
partitioned into two layers and Our Own N-layered Integrated molecular Orbital and molecular 
Mechanics, ONIOM[24-26] (QM/MM) method was used to investigate the mechanism of the 
reaction.  All counterions and the explicit water box were removed.  The QM/MM regions, 
amino acids and water molecules around 6 Å around the active site were fully optimized, while 
others more than 6 Å were held fixed[27, 28].  Construction of starting structures for finding 
the respective transition states was obtained as follows:  Crucial transition state (TS) 
interatomic distances (Fig. 2) were constrained using similar distances as previously 
reported[29] for LdtMt2, followed by partial optimization.  The cysteine catalytic active site 
(Cys360), all the selected β-lactams and water molecule were placed at a high layer [B3LYP/6-
31+G(d)4] while the other residues were at the low layer (AMBER) for geometry optimization.  
The intrinsic reaction coordinates (IRC) calculations were computed to verify the calculated 
transition states proceeded from the reactant to the product.  A full geometry optimization of 
the obtained transition states, reactant and product were performed.  Thereafter, the stationary 
points were geometrically optimized vibrational frequency calculations carried to verify that 
the transition state and minimized one and no imaginary frequencies, respectively.  Single-
point energy calculations were performed on the optimized structures of the transition states, 
reactant and product, resorting to the electronic embedding scheme with the different 
functionals (B3LYP, MO6, wb97X) and a higher 6-311+G(2d,2p) basis set which 
combinations have been known to be excellent for thermodynamics and kinetics 
calculations[26, 30, 31].  To obtain the frontier orbital (HOMO, LUMO) of β-lactams 1-6 
complexed with LdtMt5, we used B3LYP/6 31G(d,p) functional.  The donor–acceptor 




Fig. 2.  2D structure of the 6-membered ring transition states starting structures obtained using 
constraints with ONIOM (B3LYP/6-31+G(d):AMBER), where a = 1.64 Å, b = 2.14 Å, c = 
1.60 Å, d = 1.58 Å, e = 1.3 Å, f = 1.3 Å.  The TS optimized coordinates of all enzyme-inhibitor 
complexes are provided in the supplementary material) 
3.1.2 Second-order perturbation analysis 
NBO analysis is used to interpret the extent and function of intermolecular orbital interactions 
in the molecular system, principally charge transfer[32, 33].  The second-order perturbation 
theory is applied to estimate the energetic importance of all interactions between filled donor 
and empty acceptor NBOs. For each donor NBO (i) and acceptor NBO (j), the stabilization 
energy E(2) associated with delocalization is estimated as: 




Where 𝑞𝑗 is the donor orbital occupancy, 𝜀𝑖 and 𝜀𝑗 are diagonal matrix elements and 𝐹(𝑖, 𝑗) is 
the off-diagonal Fock matrix element. 
3.1.3 Frontier molecular (FMO) orbitals 
The electronic interaction between the donor and acceptor as well as the electron transfer in the 
molecular system principally relies on the spatial position of the FMO[34].  The kinetic 
characteristics of reactants and reactions are assessed by considering only FMO 
interactions[35].  To achieve this, the highest occupied molecular orbitals (HOMOs) and lowest 
unoccupied molecular orbitals (LUMOs) energies and the molecular orbital contributions were 
calculated using DFT[36-38].   
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3.2 Results and discussion 
3.2.1 Mechanistic study 
The activation free energies, enthalpies and entropies of the selected compounds, complexed 
with LdtMt5 for the 6-membered ring reaction pathway of the acylation are listed in Table 1.  
To investigate the accuracy and sensitivity of different functionals and method used, single 
point energy calculations of the respective structures (reactants, transition states and products) 
were performed using electronic embedding with B3LYP, M06-2X and ωB97X with 6-
311++G(2d, 2p) basis set which have been reported to perform reasonable for kinetic and 
thermodynamic analysis[26, 30, 31].  In our previous study, the critical catalytic role of water, 
known to play an vital role in reaction mechanism has been demonstrated[9, 17].  The kinetic 
parameters obtained from the proposed model with water (TS-6-water) showed a lower 
activation barrier when compared with the model without water in LdtMt2[17]. The catalytic 
behaviour of the acylation of Cys360 in LdtMt5 with one water molecule in the binding pocket 
against the selected β-lactams compounds was investigated.  As shown in Table 1, the lowest 
activation energy (∆G#) is obtained with B3LYP/6-311++G(2d,2p) basis set, and thus our 
elucidation will be based on the results from this functional. The 6-membered ring transition 
state ∆G# of compounds 2-6 differs by about 1 kcal mol-1 while compound 1 showed the lowest 
activation barrier (Table 1).  A comparison of the ΔH values of the transition states for 
compounds 1-6 revealed that they are consistent with the results obtained for the calculated 
∆G#.  
Our results also reveal that our proposed 6-membered ring transition state mechanism is 
comparable to the activation energies of the 6-membered ring TS of LdtMt2 achieved 
previously[29] in our group using the same functional and basis set.  In addition, the results 
revealed that this TS model with thermal corrections has a smaller value (between 14 and 28 
kcal mol-1) for LdtMt5 compared to the ∆G# 19.98 and 24.55 kcal mol-1 for a similar concerted 
pathway for imipenem and meropenem complexed with LdtMt2[29].  Meanwhile, a higher  ∆G# 
53.29 and 91.08 kcal mol-1 for imipenem and meropenem against LdtMt5 respectively was 
previously observed[39].  Meropenem and imipenem were tested experimentally against 
LdtMt5, both drugs were reported to show slow acylation which indicates possibly higher 
activation energies.  
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Table 1.  Relative energy, ΔH (kcal mol-1) and ΔS (kcal mol-1) of LdtMt5 for the 6-membered ring reaction pathway of the acylation step 
obtained in ONIOM model using different density functionals at 6-311++G(2d,2p):AMBER 
aEnergies relative to reactant for total electronic energy (ΔE) and activation free energy (ΔG#, with thermal correction) using B3LYP, M06, 
ωB97X/6-311++G(d,p):AMBER//B3LYP/6-31G(d,p):AMBER. R = reactant, TS = transition state and Pr = product.  (The TS optimized 
coordinates of enzyme-inhibitor complexes are provided in the supplementary material) 
Compounds   
  
R 




ΔE ΔG# ΔH ΔS ΔE ΔG# ΔH ΔS ΔE ΔG# ΔH ΔS 
0 0 0 0 0 0 0 0 0 0 0 0 
TS 17.36 13.67 13.41 0.26 21.71 18.03 17.77 0.26 23.08 19.39 19.13 0.26 
Pr -19.39 -19.36 -18 -1.36 -18.75 -18.72 -17.35 -1.37 -18.94 -18.91 -17.54 -1.37 
2 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 22.62 20.9 18.75 2.15 25.89 23.02 22.02 1.00 28.19 26.46 24.32 2.14 
Pr -19.66 -16.79 -19.75 2.96 12.12 14.99 12.03 2.96 13.66 16.54 13.57 2.97 
3 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 23.65 22.88 18.9 3.98 27.5 26.73 28.78 -2.05 28.69 27.92 23.95 3.97 
Pr -14.23 -12.96 -14.28 1.32 -11.6 -10.32 -11.65 1.33 -13.74 -12.47 -13.79 1.32 
4 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 25.01 24.29 21.68 2.61 27.33 26.62 24.01 2.61 30.77 30.05 27.44 2.61 
Pr -6.26 -4.69 -4.93 0.24 -4.48 -2.91 -3.16 0.25 -5.26 -3.68 -3.93 0.25 
5 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 29.3 27.86 25.62 2.24 32.15 30.71 28.47 2.24 34.12 32.69 30.44 2.25 
Pr -9.88 -8.46 -8.41 -0.05 -7.69 -6.27 -6.22 -0.05 -9.11 -7.68 -7.64 -0.04 
6 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 28.33 28.26 21.54 6.72 33 32.91 26.2 6.71 38.22 38.14 31.42 6.72 
Pr -24.68 -23.23 -22.06 -1.17 -21.83 -20.38 -19.22 -1.16 -20.18 -18.73 -17.57 -1.16 
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Based on the results shown in Table 1 and Fig. 3, compound 1 is the most reactive inhibitor in 
comparison to the other compounds.   
Fig. 3. Gibbs free energy pathway for the 6-membered ring mechanism of inhibition of L,D-
transpeptidase (LdtMt5) by the β-lactams compounds obtained at (ONIOM) B3LYP/6-
311++G(2d,2p):AMBER, extrapolated from Table 1.  See Fig. 1 for the structure of the inhibitors 
3.2.2 Frontier molecular orbitals and electrostatic potential mapping 
The difference in the LUMO-HOMO, also known as the energy gap helps to characterize the 
chemical reactivity and kinetic stability of a molecule[40].  The frontier molecular orbitals 
(LUMO-HOMO) of β-lactams plot is shown in Fig. S3.  This energy gap for the studied 
compounds calculated by B3LYP/6-31G(d,p) is presented in Table S1.  The order of reactivity 
ranges from the lowest to highest in the order 2 < 1 < 3 < 4 < 5 < 6.  This order relatively 
follows the same order base on the ΔG# of the covalently bonded product formed after the 
acylation (Table 1), which indicates how fast or slow the kinetics of the reaction are.  Molecular 
electrostatic potential (ESP) calculations of the transition states structures were surface mapped 
and this parameter was then used to depict the size, shape, charge density and reactive sites of 
the molecules[41, 42].  The mapped surface of the different compounds is presented in Fig. 4.  
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The values of the electrostatic potential are signified by various colours; red denotes the regions 
of the most negative electrostatic potential, blue signifies the regions of the most positive 
electrostatic potential and green represents the region of zero potential[43].  Fig. 4 gives a 
pictorial representation of the nucleophilic sites and relative reactivity of atoms.  It is evident 
in all the compounds that the site of nucleophilic attack between the Sγ and C3 atoms (red 










Fig. 4. Molecular electrostatic potential surface of selected compounds  
3.2.3 Natural bond orbital (NBO) analysis 
Charge transfer, viz from donor (bond or lone pair) to acceptor corresponding to a stabilizing 
donor-acceptor interaction can be calculated using NBO analysis.  The charge transfer between 
the β-lactam-LdtMt5 complexes is of paramount importance.  The resulted donor, acceptor 
orbitals and energy of stabilization E2  is derived from the second-perturbation theory[44, 45].  
-6.736e-2 6.736e
-2 





A larger E2 value indicates a stronger interaction between the electron-donors and electron-
acceptors, i.e. the more donating tendency from donors to acceptors the greater the extent of 
conjugation of the whole system[46].  In other words, a larger E2 value contributes to a lower 
energy.  The pictorial representation of the electron transfer for lactams-LdtMt5 complexes 
derived from this analysis is shown in Fig. 5.  
 
Fig. 5. Depiction of electron transfer for β-lactams/LdtMt5 complexes derived from second-order 
perturbation theory of NBO analysis.  The curved arrows (a, b and c) depict the direction of charge 
transfer from lone pair to antibonding (LP→σ٭). (The TS optimized coordinates are provided in the 
supplementary material)  
As presented in Table 2, the 6-membered ring, stabilization energy E2 for the nucleophilic 
attack on the carbonyl group of compounds 4, 3, 5, 6, 2 and 1 by the thio group of Cys360 are 
8.01, 6.16, 5.49, 3.40, 1.87 and 0.91 kcal mol-1 respectively. These values showed that the 
carbapenems have more nucleophilic attack in comparison to the monobactam.  The E2 value 
of the 6-membered ring transition states for each complex from a lone pair (LP) of the Sγ atom 
of the donor to the acceptor (C3).  The concerted proton transfer to the β-lactam nitrogen 
[LP(Nβ)-LP
*(He)] revealed compound 5 and 6 (1.64 and 1.49 kcal mol
-1,  respectively) as the 
highest while compound 2 (1.00 kcal mol-1) the lowest.  The result follows a similar trend with 






Table 2.  Second-order perturbation stabilization energies corresponding to the core intermolecular 
charge transfer interaction (Donor to Acceptor) of the LdtMt5 for 6-membered transition states of 




ZINC03788344   
LP (Sγ) δ*(C3-O2) 0.91 
LP (H42) 
       δ*(N6-
C7) 
1.06 
ZINC02462884   
LP (Sγ) δ*(C3-O2) 1.87 
LP*(H21) 
       δ*(N2-
C3) 
1 
ZINC03791246   
LP (Sγ) δ*(C3-O2) 6.16 
LP*(H21) 
       δ*(N2-
C30) 
1.17 
ZINC03808351   
LP (Sγ) δ*(C3-O2) 8.01 
LP*(O-H21) 
       δ*(N2-
C3) 
0.14 
ZINC03784242   
LP (Sγ) δ*(C3-O2) 5.49 
LP (H41) 
       δ*(N5-
C9) 
1.64 
ZINC02475683   
LP (Sγ) δ*(C3-O2) 3.4 
LP* (H20) 





Due to the relatively weak in vitro inhibition of LdtMt5 by carbapenem drugs currently 
employed, we used the β-lactam ring as a scaffold to screen similar compounds in the ZINC 
database to see their kinetic behaviour with this enzyme.  In this study, we investigated the 
acylation step of LdtMt5 by employing QM/MM (ONIOM) calculations.  The 6-membered ring 
mechanisms were investigated for the acylation reaction path of LdtMt5 with six selected β-
lactams from the ZINC database.  The activation free energy (∆G#) obtained from the 6-
membered ring TS revealed that all the β-lactams were thermodynamically favourable than 
previously calculated ∆G#  for imipenem and meropenem complexed with LdtMt5.  Meropenem 
and imipenem were tested experimentally against LdtMt5, both drugs were reported to show 
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slow acylation which indicate possibly higher activation energies. The obtained results are 
comparable to those observed for LdtMt2 albeit, for compound 1 the activation energy is 
considerably lower than that obtained for meropenem and imipenem in complexed with LdtMt2.  
This suggest that compound 1 should in theory be a very potent inhibitor of LdtMt5.   
The LUMO-HOMO energy gap values of the compounds are small suggestive of their 
structural stability.  ESP revealed that the site of reaction are chemically active sites viz the 
interaction of the lactam ring with the cysteine of LdtMt5.  It is important to stress that this study 
has in addition to the previously reported efficacies for carbapenems, the selected β-lactam 
derivatives which showed a lower energy barrier difference found in acylation with LdtMt5.  
Consequently, these findings should be subject to experimental bioactivities of this enzyme, 
more specifically binding thermodynamics assays i.e. isothermal titration calorimetry. 
Feedback from that will assist us to better validate our theorical model and aid rational design 
of new compounds and potential drug candidates with higher inhibitory activity against M.tb.  
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Recombinant proteins are the backbone of the biopharmaceutical industry1.  They are important 
primarily in the structural determination of drug targets and the development of small molecule 
novel drugs1, 2.  Proteins are complex in structure and function therefore they can hardly be 
synthesised chemically, hence they require a biological host cell2.  Bacterial hosts are common 
in the synthesis of recombinant proteins, and E. coli is so often the candidate because it is 
relatively easy to manipulate, economical and high yielding, in a process known as 
overexpression3, 4.  The BL21 (DE3) strain is popular for protein expression5.  After expression 
the protein needs to be isolated, a process known as purification.  This enables the protein to 
be structurally evaluated and functionally characterised.  Affinity chromatography (metal 
binding) is widely used to purify recombinant proteins expressed in bacteria6.  A pure protein 
can easily be evaluated for structure-function relationships with other biological or chemical 
compounds.  Thermodynamics are a good measure of protein-ligand interactions7, 8.  Isothermal 
titration calorimetry (ITC) is an ideal technique to validate theoretical structure-based binding 
energies since it is capable of resolving the entropic and enthalpic elements of binding affinity9.  
In this chapter, the primary focus was on experimental validation.  In order to validate the 
previously reported virtual screening model and the binding energies of the compounds which 
were obtained against LdtMt5, one compound (with the highest binding energy) was selected 
and prepared for a further binding thermodynamics analysis.  A lyophilised pET28a-LdtMt5 
plasmid was obtained from Johns Hopkins University.  
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4.1 Materials and Methods 
4.1.1 Expression and Extraction of LdtMt5 
The lyophilised pET28a-LdtMt5 (10 µg) plasmid was reconstituted in 50 µL nuclease-free 
water.  The plasmid was used to transform E. coli strain BL21 (DE3) using the heat shock 
method.  A single colony from the transformation was used to inoculate 5mL of Luria-Bertani 
(LB) medium containing 34 μg/mL of kanamycin and 34 μg/mL of chloramphenicol (LBAC 
medium) and was incubated overnight at 37 °C in a shaker.  From the overnight culture, 1 mL 
was transferred into 500 mL flasks containing 100 mL of fresh LBAC (initial OD600 = 0.05).  
Cell growth was regulated at 37 °C and to induce protein overexpression, 0.1 mM isopropyl 1-
thio-β-D-galactopyranoside (IPTG) was added at early exponential phase (OD600 between 0.5 
- 0.7).  The flasks were then transferred to 16 °C and left to grow on a shaker incubator 
(200rpm) overnight.  Following induction, cells were harvested by centrifugation at 5000 x g 
at 4 °C for 10 minutes, and 10 mL of buffer A [10 mM Tris-HCl, pH 7.9 containing 1 mM 
phenylmethylsulfonyl fluoride (PMSF)] was used to resuspend the pellet.  Sonication (Omni 
International Sonic Ruptor 400 Ultrasonic homogenizer) at the frequency of 20 kHz was 
performed to prepare the crude cell extracts.  To minimize thermal effects, the sonication 
sample was placed on ice and for a period of 10 minutes at 20 % amplitude, the homogenized 
sample was subjected to 30 seconds on / 30 seconds off pulses.  The sonicated samples were 
then centrifuged for 20 minutes at 13,000 x g at 4 °C (Beckman Centrifuge). 
4.1.2 Purification of the Protein 
Purification of the protein was conducted using the AKTA purifier 100-950 (GE Health Care).  
A His Pur Cobalt column, 5 mL, (Thermo Scientific) was used to purify the fusion protein.  
Firstly, the column was equilibrated with a 10-column volume of equilibration buffer (50 mM 
Na2PO4, pH 7.5, 300 mM NaCl, 5 mM imidazole).  The protein sample (20 mL) was loaded 
onto the column using a sample pump.  The column was washed with 5 column volumes of the 
same buffer to remove unbound proteins.  Bound proteins (LdtMt5) were then eluted using 
elution buffer (50 mM Na2PO4, pH 7.5, 300 mM NaCl, 150 mM imidazole).  SDS-PAGE was 
used to verify the purity of the eluted protein fraction10. 
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4.1.3 Molecular weight and protein profile determination by SDS-PAGE 
The method by Laemmli (1970) was adopted to determine the protein profile10.  An initial 
preparation of a resolving gel (composed of 10 % [v/v] acrylamide, 0.1 % [v/v] sodium dodecyl 
sulphate [SDS] in 1.5 M Tris-HCl, pH 8.8) was cast on a vertical slab and this was followed 
by a stacking gel (5 % [v/v] acrylamide, 0.1 % [v/v] SDS in 1 M Tris-HCl, pH 6.8) which was 
layered above the initial cast.  A stock solution of acrylamide [30 % (w/v)] was formulated by 
adding 29 g of acrylamide and 1 g of N,N'-methylbisacrylamide to 80 mL dH2O which was 
adjusted to a 100 mL final volume.  A solution composed for 5 µL of 6X SDS loading dye and 
25 µL protein samples was added into eppendorf tubes and the samples were boiled for 5 
minutes in a water-bath.  The solution was loaded onto the gel which was run at a voltage of 
80 V in 1 X SDS running buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS) for a period of 1.5 
hours.  For improved visibility, the gel was soaked in Coomassie staining solution for 2 hours.  
The gel was then destained in solution of 10 % (v/v) methanol containing 10 % (v/v) acetic 
acid.  The protein profile in the gel was captured using a UV-transilluminator (Syngene; 
Syoptics Ltd, Cambridge, UK). 
4.1.4 Calorimetric Studies 
LdtMt5 protein was dialysed overnight in a 5 L buffer of 25 mM Tris-HCl at pH 7.5, 100 mM 
NaCl at 4 °C.  The dialysed protein was filtered through a 0.22 μm filter and diluted to a 
concentration of 10 μM buffer (25 mM Tris-HCl at pH 7.5, 100 mM NaCl, 1 mM DTT) with 
2 % DMSO.  Aliquots of ligand solutions were diluted to 100 μM in the protein dialysis buffer 
containing 2 % DMSO.  The samples (protein and ligand) were then degassed for 10 minutes 
in a ThermaVac®.  Ligand injections (10 μL) into the cell containing LdtMt5 were performed 
with 240-second equilibrations between injections.  Calorimetry experiments were performed 





4.2.1 Expression and Purification of LdtMt5 
Protein expression was achieved by growing a culture at 16 °C as seen by the thick band around 
50 kDa, Figure 1.  The expressed LdtMt5 contained an N-Terminal His-tag, which was used for 
purification.  Purification was achieved by loading the crude lysate into a cobalt column.  The 
protein fusion protein was purified with a single step purification procedure.  Figure 1 shows 
a chromatogram of LdtMt5 fusion protein and protein profile. 
 
Figure 1.  Purification of LdtMt5 fusion protein using affinity chromatography.  The cell lysate was 
loaded onto a His Pur cobalt column previously equilibrated with 50 mM Na2PO4, 300 mM, NaCl and 
5 mM imidazole.  Unbound proteins were washed out with 5 column volumes of the same buffer and 
bound proteins were eluted with same buffer but with 0-250 mM imidazole gradient.  Purity was verified 
using SDS-PAGE.  A; chromatogram showing bound and unbound fractions.  B; SDS-PAGE of the 
collected fractions, MWM; Molecular weight marker; 1 crude protein, 2 unbound protein, 3-5 bound 
proteins 
4.2.2 Isothermal Titration Calorimetry 
The compound (ZINC02475683) with the highest calculated binding energy was selected for 
further binding thermodynamics analysis of binding to LdtMt5 using ITC.  The ligand (CAS 
330960-03-7) compound name, 1H-Isoindole-1,3(2H)-dione, 2-[2-(1,3-benzodioxol-5-yl)-1-
(3-chloro-4-methylphenyl)-4-oxo-3-azetidinyl]-4-nitro- was commercially available and the 












Figure 2.  The chemical structure of the ligand used to evaluate the thermodynamics of binding to 
LdtMt5 using ITC 
The isothermal titration calorimetry results reveal that no significant heat exchange associated 
with binding was measured as shown in Figure 3. 
 
Figure 3.  ITC of compound A binding to LdtMt5.  Upper panel shows titration of the LdtMt5 with 
compound A.  Lower panel is a plot of the total heat released as a function of total ligand concentration 




According to the ITC performed in this study, results showed no binding of the lead compound 
which exhibited the highest affinity to LdtMt5 through calculated free binding energies.  It is 
important to highlight the extremely low solubility involved with the compound under study.  
The compound is a β-lactam, more specifically a monobactam and these compounds are well 
known for being highly insoluble.  The same could have potentially played a negative role in 
the binding to the active site of LdtMt5. 
The findings revealed by the experimental study by Basta et al. by means of the same 
experimental technique in which a series of β-lactams including the carbapenems were 
evaluated, and measured the thermodynamics of binding to this protein was performed11.  
However, our experimental evaluation was also performed on a β-lactam but a monobactam, 
so it cannot be effectively compared to carbapenems.  Also, a single β-lactam compound is 
insufficient statistically to draw up a concrete conclusion on. 
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Conclusion and recommendations 
The first part of the study (Chapter 2) sought to address the question of lack of known inhibitors 
for LdtMt5.  Throughout literature, no virtual screening study had been performed for L,D-
transpeptidases, more importantly for the protein under study LdtMt5.  In humans, carbapenems 
are considered the last resort antibiotics against bacteria but unfortunately, they have extremely 
limited effect on LdtMt5 thus prompting the search for potential inhibitors against the protein.  
L,D-transpeptidases are peptidoglycan polymerases which catalyse the formation of 3→3 
peptidoglycan cross-links (80 %, unique to M.tb) and are essential in the biosynthesis of the 
cell wall through which antibiotic resistance is accomplished.  Among the five M.tb Ldt 
paralogs, the most dominant and widely studied is LdtMt2.  Studies on antibacterial activity of 
carbapenems on Ldts revealed that LdtMt5 remained active in the peptidoglycan cross-linking 
assay, thus inferring unique characteristics of the protein.  It was also shown that M.tb lacking 
a functional copy of LdtMt5 was vulnerable to denaturation.  This typically necessitated the 
screening of compounds for potent leads against LdtMt5. 
Our virtual screening for prospective compounds against LdtMt5 successfully identified many 
potential novel inhibitors which came from four different classes of antimicrobial compounds.  
It is important to note that β-lactams, more specifically carbapenems were among the 
successfully screened compounds with high binding affinity for the protein under study.  The 
MD simulations also revealed favourable binding affinity of compounds from all classes, with 
the highest affinity being the β-lactam class.  However, since it is known that certain β-lactams 
(carbapenems) inhibit LdtMt2 but not effectively LdtMt5, it is therefore plausible that the 
evaluation of the binding thermodynamics and mechanistic studies be performed from all four 
classes of antimicrobial compounds obtained from virtual screening against LdtMt5.  This is due 
to the lack of known experimental binding thermodynamics and inhibition mechanism for 
LdtMt5.  The β-lactams obtained in this study are novel and different from the ones evaluated in 
the other studies on LdtMt5 as well as on any Ldt belonging to M.tb so it is worthwhile to 
investigate their effect on the protein.  The current study has served as a reference point in 
which the identified compounds can be further analysed experimentally for bioactivity (in vitro 
and in vivo), thus assist in the validation of the model and also providing a better understanding 
of the protein’s inhibition and binding mechanism.  It also formed the basis of the second study 
(Chapter 3) on the mechanism of action of β-lactams on LdtMt5. 
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In the current study (Chapter 2) we also performed a dual virtual screening approach in which 
two software programs were applied to the screening.  This is an improvement on other virtual 
screening studies which screen chemical compound databases using a single program.  The 
study revealed an important aspect on virtual screening that, in order to increase the chance of 
acquiring many leads, it is highly recommended that one performs the screening using two or 
more software with different search algorithms.  Such an approach can enable the researcher 
to thoroughly explore the chemical search space and obtain a comprehensive screen in which 
many lead compounds are evaluated.  Also, the general consensus among the different software 
programs on common potential leads can eliminate the need to perform MD simulations, thus 
saving time and computational resources. 
Computational procedures have been employed to study this catalytic mechanism, which 
corroborates experimental observations for the mechanism of LdtMt2.  The first reported 
catalytic mechanism of L,D-transpeptidase of M.tb suggested a dual step process in which 
firstly, the Cys354-thiolate/His336-imidazolium pair formation initiated a four membered ring 
acylation step, followed by the nucleophilic attack of Cys354 on the carbonyl carbon of the 
substrate, thereby forming a covalent intermediate.  The second step was characterised by an 
attack of the acyl-enzyme complex by the amine group (deacylation), resulting in the formation 
of the 3→3 peptide bond.  A model for the acylation step of the β-lactam ring against LdtMt2 
was more recently investigated utilizing DFT calculations, [B3LYP/6-31 + G(d)].  The 
acylation mechanisms were studied as four-membered-ring (TS-4, TS-4-His and TS-4-water) 
and six-membered ring (TS-6-water) transition states.  The thermochemical parameters for the 
proposed models were obtained and it was established that the activation barrier of TS-6-water 
model was considerably lower than the other models. 
The same DFT approach utilized from the previously mentioned study was adopted in this 
study (Chapter 3) using the full protein (LdtMt5) and the 6-membered ring transition states were 
obtained using constraints.  We performed a two-stage minimization of the geometry which 
included a catalytic water molecule inserted in the active site.  The complex from the MD run 
was partitioned into two layers and the ONIOM (QM/MM) approach was applied to investigate 
the mechanism of the reaction.  The activation free energies of some virtually screened β-
lactam compounds obtained from ONIOM (QM/MM) study gave insight on their reactivities.  
This describes the acylation mechanism involving the attack of the S-H group of cysteine active 
site residue of LdtMt5.  Our results showed that the ∆G# is comparable with obtained results for 
LdtMt2 from other studies, indicative of the reactivity of the screened compounds. 
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The experimental section (Chapter 4) of the present study exhibited exceptionally good protein 
expression and purification as revealed by the affinity chromatogram and the SDS-PAGE.  
However, the binding analysis from the ITC exhibited limited binding affinity of the compound 
to the protein.  At this point one cannot conclusively determine the cause of the lack of binding 
whether it is due to the protein binding-induced conformational changes or it is wholly due to 
poor solubility of the compound.  Because of time constraints, limited financial and technical 
resources, we were unable to continue evaluating the binding dynamics.  We therefore 
recommend that further fluorescent ligand binding assays can be performed to detect the 
binding of the ligand or a known substrate (nitrocefin) to the target.  Thermal denaturation 
assays (TDA) can also be performed to monitor thermal denaturation process of proteins in the 
presence of the ligands.  These assays may assist to determine the factors behind the observed 
lack of binding. 
In the present study we used a single compound (a monobactam) which had the highest binding 
affinity to the protein under study to perform the binding thermodynamics assay, ITC due to 
the constraints mentioned earlier.  A total of ten novel compounds from four different 
antimicrobial classes was obtained from our virtual screening of potential compounds against 
LdtMt5.  From the β-lactam class, five potential leads were obtained from the screen in which 
two were monobactams and three were carbapenems.  Since certain carbapenems have 
previously been shown to be active against LdtMt2 but having a limited effect on LdtMt5, we 
recommend that the binding thermodynamics assays be performed on these compounds for 
comparison with findings of previous studies.  These carbapenems obtained from our virtual 
screening are novel, so evaluating their binding thermodynamics can bring about a conclusive 
understanding on carbapenems’ effectiveness on the protein.  Also, for an average statistical 
representation of the data, these three compounds would be ideal.  We also suggest that a further 
binding thermodynamics analysis of the novel compounds from other classes to be performed 
to evaluate the effect of these compound on LdtMt5.  Furthermore, if any experimental 
observations suggest possible affinity to the protein, catalytic mechanistic studies can be 
undertaken. 
 
